MIME-Version: 1.0
Content-Type: multipart/related; boundary="----=_NextPart_01DA20AF.DA67EAE0"

Данный документ является веб-страницей в одном файле, также называемой файлом веб-архива. Если вы видите это сообщение, значит, данный браузер или редактор не поддерживает файлы веб-архива. Загрузите браузер, поддерживающий веб-архивы, например Windows® Internet Explorer®.

------=_NextPart_01DA20AF.DA67EAE0
Content-Location: file:///C:/6811E755/UA174580101_B895.htm
Content-Transfer-Encoding: quoted-printable
Content-Type: text/html; charset="windows-1251"

<html xmlns:v=3D"urn:schemas-microsoft-com:vml"
xmlns:o=3D"urn:schemas-microsoft-com:office:office"
xmlns:w=3D"urn:schemas-microsoft-com:office:word"
xmlns:m=3D"http://schemas.microsoft.com/office/2004/12/omml"
xmlns=3D"http://www.w3.org/TR/REC-html40">

<head>
<meta http-equiv=3DContent-Type content=3D"text/html; charset=3Dwindows-125=
1">
<meta name=3DProgId content=3DWord.Document>
<meta name=3DGenerator content=3D"Microsoft Word 14">
<meta name=3DOriginator content=3D"Microsoft Word 14">
<link rel=3DFile-List href=3D"UA174580101_B895.files/filelist.xml">
<link rel=3DPreview href=3D"UA174580101_B895.files/preview.wmf">
<!--[if gte mso 9]><xml>
 <o:DocumentProperties>
  <o:Author>Гаврилюк Олена Іванівна</o:Author>
  <o:Template>Normal</o:Template>
  <o:LastAuthor>Bravada</o:LastAuthor>
  <o:Revision>2</o:Revision>
  <o:TotalTime>4</o:TotalTime>
  <o:Created>2023-11-26T19:31:00Z</o:Created>
  <o:LastSaved>2023-11-26T19:31:00Z</o:LastSaved>
  <o:Pages>4</o:Pages>
  <o:Words>1424</o:Words>
  <o:Characters>8120</o:Characters>
  <o:Company>JSC Farmak</o:Company>
  <o:Lines>67</o:Lines>
  <o:Paragraphs>19</o:Paragraphs>
  <o:CharactersWithSpaces>9525</o:CharactersWithSpaces>
  <o:Version>14.00</o:Version>
 </o:DocumentProperties>
 <o:OfficeDocumentSettings>
  <o:AllowPNG/>
 </o:OfficeDocumentSettings>
</xml><![endif]-->
<link rel=3DthemeData href=3D"UA174580101_B895.files/themedata.thmx">
<link rel=3DcolorSchemeMapping
href=3D"UA174580101_B895.files/colorschememapping.xml">
<!--[if gte mso 9]><xml>
 <w:WordDocument>
  <w:TrackMoves>false</w:TrackMoves>
  <w:TrackFormatting/>
  <w:HyphenationZone>21</w:HyphenationZone>
  <w:PunctuationKerning/>
  <w:ValidateAgainstSchemas/>
  <w:SaveIfXMLInvalid>false</w:SaveIfXMLInvalid>
  <w:IgnoreMixedContent>false</w:IgnoreMixedContent>
  <w:AlwaysShowPlaceholderText>false</w:AlwaysShowPlaceholderText>
  <w:DoNotPromoteQF/>
  <w:LidThemeOther>RU</w:LidThemeOther>
  <w:LidThemeAsian>X-NONE</w:LidThemeAsian>
  <w:LidThemeComplexScript>X-NONE</w:LidThemeComplexScript>
  <w:Compatibility>
   <w:BreakWrappedTables/>
   <w:SnapToGridInCell/>
   <w:WrapTextWithPunct/>
   <w:UseAsianBreakRules/>
   <w:DontGrowAutofit/>
   <w:DontUseIndentAsNumberingTabStop/>
   <w:FELineBreak11/>
   <w:WW11IndentRules/>
   <w:DontAutofitConstrainedTables/>
   <w:AutofitLikeWW11/>
   <w:HangulWidthLikeWW11/>
   <w:UseNormalStyleForList/>
   <w:DontVertAlignCellWithSp/>
   <w:DontBreakConstrainedForcedTables/>
   <w:DontVertAlignInTxbx/>
   <w:Word11KerningPairs/>
   <w:CachedColBalance/>
  </w:Compatibility>
  <m:mathPr>
   <m:mathFont m:val=3D"Cambria Math"/>
   <m:brkBin m:val=3D"before"/>
   <m:brkBinSub m:val=3D"&#45;-"/>
   <m:smallFrac m:val=3D"off"/>
   <m:dispDef/>
   <m:lMargin m:val=3D"0"/>
   <m:rMargin m:val=3D"0"/>
   <m:defJc m:val=3D"centerGroup"/>
   <m:wrapIndent m:val=3D"1440"/>
   <m:intLim m:val=3D"subSup"/>
   <m:naryLim m:val=3D"undOvr"/>
  </m:mathPr></w:WordDocument>
</xml><![endif]--><!--[if gte mso 9]><xml>
 <w:LatentStyles DefLockedState=3D"false" DefUnhideWhenUsed=3D"true"
  DefSemiHidden=3D"true" DefQFormat=3D"false" DefPriority=3D"99"
  LatentStyleCount=3D"267">
  <w:LsdException Locked=3D"false" Priority=3D"0" SemiHidden=3D"false"
   UnhideWhenUsed=3D"false" QFormat=3D"true" Name=3D"Normal"/>
  <w:LsdException Locked=3D"false" Priority=3D"9" SemiHidden=3D"false"
   UnhideWhenUsed=3D"false" QFormat=3D"true" Name=3D"heading 1"/>
  <w:LsdException Locked=3D"false" Priority=3D"9" QFormat=3D"true" Name=3D"=
heading 2"/>
  <w:LsdException Locked=3D"false" Priority=3D"9" QFormat=3D"true" Name=3D"=
heading 3"/>
  <w:LsdException Locked=3D"false" Priority=3D"9" QFormat=3D"true" Name=3D"=
heading 4"/>
  <w:LsdException Locked=3D"false" Priority=3D"9" QFormat=3D"true" Name=3D"=
heading 5"/>
  <w:LsdException Locked=3D"false" Priority=3D"9" QFormat=3D"true" Name=3D"=
heading 6"/>
  <w:LsdException Locked=3D"false" Priority=3D"9" QFormat=3D"true" Name=3D"=
heading 7"/>
  <w:LsdException Locked=3D"false" Priority=3D"9" QFormat=3D"true" Name=3D"=
heading 8"/>
  <w:LsdException Locked=3D"false" Priority=3D"9" QFormat=3D"true" Name=3D"=
heading 9"/>
  <w:LsdException Locked=3D"false" Priority=3D"39" Name=3D"toc 1"/>
  <w:LsdException Locked=3D"false" Priority=3D"39" Name=3D"toc 2"/>
  <w:LsdException Locked=3D"false" Priority=3D"39" Name=3D"toc 3"/>
  <w:LsdException Locked=3D"false" Priority=3D"39" Name=3D"toc 4"/>
  <w:LsdException Locked=3D"false" Priority=3D"39" Name=3D"toc 5"/>
  <w:LsdException Locked=3D"false" Priority=3D"39" Name=3D"toc 6"/>
  <w:LsdException Locked=3D"false" Priority=3D"39" Name=3D"toc 7"/>
  <w:LsdException Locked=3D"false" Priority=3D"39" Name=3D"toc 8"/>
  <w:LsdException Locked=3D"false" Priority=3D"39" Name=3D"toc 9"/>
  <w:LsdException Locked=3D"false" Priority=3D"35" QFormat=3D"true" Name=3D=
"caption"/>
  <w:LsdException Locked=3D"false" Priority=3D"10" SemiHidden=3D"false"
   UnhideWhenUsed=3D"false" QFormat=3D"true" Name=3D"Title"/>
  <w:LsdException Locked=3D"false" Priority=3D"1" Name=3D"Default Paragraph=
 Font"/>
  <w:LsdException Locked=3D"false" Priority=3D"11" SemiHidden=3D"false"
   UnhideWhenUsed=3D"false" QFormat=3D"true" Name=3D"Subtitle"/>
  <w:LsdException Locked=3D"false" Priority=3D"22" SemiHidden=3D"false"
   UnhideWhenUsed=3D"false" QFormat=3D"true" Name=3D"Strong"/>
  <w:LsdException Locked=3D"false" Priority=3D"20" SemiHidden=3D"false"
   UnhideWhenUsed=3D"false" QFormat=3D"true" Name=3D"Emphasis"/>
  <w:LsdException Locked=3D"false" Priority=3D"39" SemiHidden=3D"false"
   UnhideWhenUsed=3D"false" Name=3D"Table Grid"/>
  <w:LsdException Locked=3D"false" UnhideWhenUsed=3D"false" Name=3D"Placeho=
lder Text"/>
  <w:LsdException Locked=3D"false" Priority=3D"1" SemiHidden=3D"false"
   UnhideWhenUsed=3D"false" QFormat=3D"true" Name=3D"No Spacing"/>
  <w:LsdException Locked=3D"false" Priority=3D"60" Name=3D"Light Shading"/>
  <w:LsdException Locked=3D"false" Priority=3D"61" Name=3D"Light List"/>
  <w:LsdException Locked=3D"false" Priority=3D"62" Name=3D"Light Grid"/>
  <w:LsdException Locked=3D"false" Priority=3D"63" Name=3D"Medium Shading 1=
"/>
  <w:LsdException Locked=3D"false" Priority=3D"64" Name=3D"Medium Shading 2=
"/>
  <w:LsdException Locked=3D"false" Priority=3D"65" Name=3D"Medium List 1"/>
  <w:LsdException Locked=3D"false" Priority=3D"66" Name=3D"Medium List 2"/>
  <w:LsdException Locked=3D"false" Priority=3D"67" Name=3D"Medium Grid 1"/>
  <w:LsdException Locked=3D"false" Priority=3D"68" Name=3D"Medium Grid 2"/>
  <w:LsdException Locked=3D"false" Priority=3D"69" Name=3D"Medium Grid 3"/>
  <w:LsdException Locked=3D"false" Priority=3D"70" Name=3D"Dark List"/>
  <w:LsdException Locked=3D"false" Priority=3D"71" Name=3D"Colorful Shading=
"/>
  <w:LsdException Locked=3D"false" Priority=3D"72" Name=3D"Colorful List"/>
  <w:LsdException Locked=3D"false" Priority=3D"73" Name=3D"Colorful Grid"/>
  <w:LsdException Locked=3D"false" Priority=3D"60" Name=3D"Light Shading Ac=
cent 1"/>
  <w:LsdException Locked=3D"false" Priority=3D"61" Name=3D"Light List Accen=
t 1"/>
  <w:LsdException Locked=3D"false" Priority=3D"62" Name=3D"Light Grid Accen=
t 1"/>
  <w:LsdException Locked=3D"false" Priority=3D"63" Name=3D"Medium Shading 1=
 Accent 1"/>
  <w:LsdException Locked=3D"false" Priority=3D"64" Name=3D"Medium Shading 2=
 Accent 1"/>
  <w:LsdException Locked=3D"false" Priority=3D"65" Name=3D"Medium List 1 Ac=
cent 1"/>
  <w:LsdException Locked=3D"false" UnhideWhenUsed=3D"false" Name=3D"Revisio=
n"/>
  <w:LsdException Locked=3D"false" Priority=3D"34" SemiHidden=3D"false"
   UnhideWhenUsed=3D"false" QFormat=3D"true" Name=3D"List Paragraph"/>
  <w:LsdException Locked=3D"false" Priority=3D"29" SemiHidden=3D"false"
   UnhideWhenUsed=3D"false" QFormat=3D"true" Name=3D"Quote"/>
  <w:LsdException Locked=3D"false" Priority=3D"30" SemiHidden=3D"false"
   UnhideWhenUsed=3D"false" QFormat=3D"true" Name=3D"Intense Quote"/>
  <w:LsdException Locked=3D"false" Priority=3D"66" Name=3D"Medium List 2 Ac=
cent 1"/>
  <w:LsdException Locked=3D"false" Priority=3D"67" Name=3D"Medium Grid 1 Ac=
cent 1"/>
  <w:LsdException Locked=3D"false" Priority=3D"68" Name=3D"Medium Grid 2 Ac=
cent 1"/>
  <w:LsdException Locked=3D"false" Priority=3D"69" Name=3D"Medium Grid 3 Ac=
cent 1"/>
  <w:LsdException Locked=3D"false" Priority=3D"70" Name=3D"Dark List Accent=
 1"/>
  <w:LsdException Locked=3D"false" Priority=3D"71" Name=3D"Colorful Shading=
 Accent 1"/>
  <w:LsdException Locked=3D"false" Priority=3D"72" Name=3D"Colorful List Ac=
cent 1"/>
  <w:LsdException Locked=3D"false" Priority=3D"73" Name=3D"Colorful Grid Ac=
cent 1"/>
  <w:LsdException Locked=3D"false" Priority=3D"60" Name=3D"Light Shading Ac=
cent 2"/>
  <w:LsdException Locked=3D"false" Priority=3D"61" Name=3D"Light List Accen=
t 2"/>
  <w:LsdException Locked=3D"false" Priority=3D"62" Name=3D"Light Grid Accen=
t 2"/>
  <w:LsdException Locked=3D"false" Priority=3D"63" Name=3D"Medium Shading 1=
 Accent 2"/>
  <w:LsdException Locked=3D"false" Priority=3D"64" Name=3D"Medium Shading 2=
 Accent 2"/>
  <w:LsdException Locked=3D"false" Priority=3D"65" Name=3D"Medium List 1 Ac=
cent 2"/>
  <w:LsdException Locked=3D"false" Priority=3D"66" Name=3D"Medium List 2 Ac=
cent 2"/>
  <w:LsdException Locked=3D"false" Priority=3D"67" Name=3D"Medium Grid 1 Ac=
cent 2"/>
  <w:LsdException Locked=3D"false" Priority=3D"68" Name=3D"Medium Grid 2 Ac=
cent 2"/>
  <w:LsdException Locked=3D"false" Priority=3D"69" Name=3D"Medium Grid 3 Ac=
cent 2"/>
  <w:LsdException Locked=3D"false" Priority=3D"70" Name=3D"Dark List Accent=
 2"/>
  <w:LsdException Locked=3D"false" Priority=3D"71" Name=3D"Colorful Shading=
 Accent 2"/>
  <w:LsdException Locked=3D"false" Priority=3D"72" Name=3D"Colorful List Ac=
cent 2"/>
  <w:LsdException Locked=3D"false" Priority=3D"73" Name=3D"Colorful Grid Ac=
cent 2"/>
  <w:LsdException Locked=3D"false" Priority=3D"60" Name=3D"Light Shading Ac=
cent 3"/>
  <w:LsdException Locked=3D"false" Priority=3D"61" Name=3D"Light List Accen=
t 3"/>
  <w:LsdException Locked=3D"false" Priority=3D"62" Name=3D"Light Grid Accen=
t 3"/>
  <w:LsdException Locked=3D"false" Priority=3D"63" Name=3D"Medium Shading 1=
 Accent 3"/>
  <w:LsdException Locked=3D"false" Priority=3D"64" Name=3D"Medium Shading 2=
 Accent 3"/>
  <w:LsdException Locked=3D"false" Priority=3D"65" Name=3D"Medium List 1 Ac=
cent 3"/>
  <w:LsdException Locked=3D"false" Priority=3D"66" Name=3D"Medium List 2 Ac=
cent 3"/>
  <w:LsdException Locked=3D"false" Priority=3D"67" Name=3D"Medium Grid 1 Ac=
cent 3"/>
  <w:LsdException Locked=3D"false" Priority=3D"68" Name=3D"Medium Grid 2 Ac=
cent 3"/>
  <w:LsdException Locked=3D"false" Priority=3D"69" Name=3D"Medium Grid 3 Ac=
cent 3"/>
  <w:LsdException Locked=3D"false" Priority=3D"70" Name=3D"Dark List Accent=
 3"/>
  <w:LsdException Locked=3D"false" Priority=3D"71" Name=3D"Colorful Shading=
 Accent 3"/>
  <w:LsdException Locked=3D"false" Priority=3D"72" Name=3D"Colorful List Ac=
cent 3"/>
  <w:LsdException Locked=3D"false" Priority=3D"73" Name=3D"Colorful Grid Ac=
cent 3"/>
  <w:LsdException Locked=3D"false" Priority=3D"60" Name=3D"Light Shading Ac=
cent 4"/>
  <w:LsdException Locked=3D"false" Priority=3D"61" Name=3D"Light List Accen=
t 4"/>
  <w:LsdException Locked=3D"false" Priority=3D"62" Name=3D"Light Grid Accen=
t 4"/>
  <w:LsdException Locked=3D"false" Priority=3D"63" Name=3D"Medium Shading 1=
 Accent 4"/>
  <w:LsdException Locked=3D"false" Priority=3D"64" Name=3D"Medium Shading 2=
 Accent 4"/>
  <w:LsdException Locked=3D"false" Priority=3D"65" Name=3D"Medium List 1 Ac=
cent 4"/>
  <w:LsdException Locked=3D"false" Priority=3D"66" Name=3D"Medium List 2 Ac=
cent 4"/>
  <w:LsdException Locked=3D"false" Priority=3D"67" Name=3D"Medium Grid 1 Ac=
cent 4"/>
  <w:LsdException Locked=3D"false" Priority=3D"68" Name=3D"Medium Grid 2 Ac=
cent 4"/>
  <w:LsdException Locked=3D"false" Priority=3D"69" Name=3D"Medium Grid 3 Ac=
cent 4"/>
  <w:LsdException Locked=3D"false" Priority=3D"70" Name=3D"Dark List Accent=
 4"/>
  <w:LsdException Locked=3D"false" Priority=3D"71" Name=3D"Colorful Shading=
 Accent 4"/>
  <w:LsdException Locked=3D"false" Priority=3D"72" Name=3D"Colorful List Ac=
cent 4"/>
  <w:LsdException Locked=3D"false" Priority=3D"73" Name=3D"Colorful Grid Ac=
cent 4"/>
  <w:LsdException Locked=3D"false" Priority=3D"60" Name=3D"Light Shading Ac=
cent 5"/>
  <w:LsdException Locked=3D"false" Priority=3D"61" Name=3D"Light List Accen=
t 5"/>
  <w:LsdException Locked=3D"false" Priority=3D"62" Name=3D"Light Grid Accen=
t 5"/>
  <w:LsdException Locked=3D"false" Priority=3D"63" Name=3D"Medium Shading 1=
 Accent 5"/>
  <w:LsdException Locked=3D"false" Priority=3D"64" Name=3D"Medium Shading 2=
 Accent 5"/>
  <w:LsdException Locked=3D"false" Priority=3D"65" Name=3D"Medium List 1 Ac=
cent 5"/>
  <w:LsdException Locked=3D"false" Priority=3D"66" Name=3D"Medium List 2 Ac=
cent 5"/>
  <w:LsdException Locked=3D"false" Priority=3D"67" Name=3D"Medium Grid 1 Ac=
cent 5"/>
  <w:LsdException Locked=3D"false" Priority=3D"68" Name=3D"Medium Grid 2 Ac=
cent 5"/>
  <w:LsdException Locked=3D"false" Priority=3D"69" Name=3D"Medium Grid 3 Ac=
cent 5"/>
  <w:LsdException Locked=3D"false" Priority=3D"70" Name=3D"Dark List Accent=
 5"/>
  <w:LsdException Locked=3D"false" Priority=3D"71" Name=3D"Colorful Shading=
 Accent 5"/>
  <w:LsdException Locked=3D"false" Priority=3D"72" Name=3D"Colorful List Ac=
cent 5"/>
  <w:LsdException Locked=3D"false" Priority=3D"73" Name=3D"Colorful Grid Ac=
cent 5"/>
  <w:LsdException Locked=3D"false" Priority=3D"60" Name=3D"Light Shading Ac=
cent 6"/>
  <w:LsdException Locked=3D"false" Priority=3D"61" Name=3D"Light List Accen=
t 6"/>
  <w:LsdException Locked=3D"false" Priority=3D"62" Name=3D"Light Grid Accen=
t 6"/>
  <w:LsdException Locked=3D"false" Priority=3D"63" Name=3D"Medium Shading 1=
 Accent 6"/>
  <w:LsdException Locked=3D"false" Priority=3D"64" Name=3D"Medium Shading 2=
 Accent 6"/>
  <w:LsdException Locked=3D"false" Priority=3D"65" Name=3D"Medium List 1 Ac=
cent 6"/>
  <w:LsdException Locked=3D"false" Priority=3D"66" Name=3D"Medium List 2 Ac=
cent 6"/>
  <w:LsdException Locked=3D"false" Priority=3D"67" Name=3D"Medium Grid 1 Ac=
cent 6"/>
  <w:LsdException Locked=3D"false" Priority=3D"68" Name=3D"Medium Grid 2 Ac=
cent 6"/>
  <w:LsdException Locked=3D"false" Priority=3D"69" Name=3D"Medium Grid 3 Ac=
cent 6"/>
  <w:LsdException Locked=3D"false" Priority=3D"70" Name=3D"Dark List Accent=
 6"/>
  <w:LsdException Locked=3D"false" Priority=3D"71" Name=3D"Colorful Shading=
 Accent 6"/>
  <w:LsdException Locked=3D"false" Priority=3D"72" Name=3D"Colorful List Ac=
cent 6"/>
  <w:LsdException Locked=3D"false" Priority=3D"73" Name=3D"Colorful Grid Ac=
cent 6"/>
  <w:LsdException Locked=3D"false" Priority=3D"19" SemiHidden=3D"false"
   UnhideWhenUsed=3D"false" QFormat=3D"true" Name=3D"Subtle Emphasis"/>
  <w:LsdException Locked=3D"false" Priority=3D"21" SemiHidden=3D"false"
   UnhideWhenUsed=3D"false" QFormat=3D"true" Name=3D"Intense Emphasis"/>
  <w:LsdException Locked=3D"false" Priority=3D"31" SemiHidden=3D"false"
   UnhideWhenUsed=3D"false" QFormat=3D"true" Name=3D"Subtle Reference"/>
  <w:LsdException Locked=3D"false" Priority=3D"32" SemiHidden=3D"false"
   UnhideWhenUsed=3D"false" QFormat=3D"true" Name=3D"Intense Reference"/>
  <w:LsdException Locked=3D"false" Priority=3D"33" SemiHidden=3D"false"
   UnhideWhenUsed=3D"false" QFormat=3D"true" Name=3D"Book Title"/>
  <w:LsdException Locked=3D"false" Priority=3D"37" Name=3D"Bibliography"/>
  <w:LsdException Locked=3D"false" Priority=3D"39" QFormat=3D"true" Name=3D=
"TOC Heading"/>
 </w:LatentStyles>
</xml><![endif]-->
<style>
<!--
 /* Font Definitions */
 @font-face
	{font-family:Wingdings;
	panose-1:5 0 0 0 0 0 0 0 0 0;
	mso-font-charset:2;
	mso-generic-font-family:auto;
	mso-font-pitch:variable;
	mso-font-signature:0 268435456 0 0 -2147483648 0;}
@font-face
	{font-family:"MS Mincho";
	panose-1:2 2 6 9 4 2 5 8 3 4;
	mso-font-alt:"\FF2D\FF33 \660E\671D";
	mso-font-charset:128;
	mso-generic-font-family:modern;
	mso-font-pitch:fixed;
	mso-font-signature:-536870145 1791491579 18 0 131231 0;}
@font-face
	{font-family:"MS Mincho";
	panose-1:2 2 6 9 4 2 5 8 3 4;
	mso-font-alt:"\FF2D\FF33 \660E\671D";
	mso-font-charset:128;
	mso-generic-font-family:modern;
	mso-font-pitch:fixed;
	mso-font-signature:-536870145 1791491579 18 0 131231 0;}
@font-face
	{font-family:"Arial Unicode MS";
	panose-1:2 11 6 4 2 2 2 2 2 4;
	mso-font-charset:128;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:-134238209 -371195905 63 0 4129279 0;}
@font-face
	{font-family:Calibri;
	panose-1:2 15 5 2 2 2 4 3 2 4;
	mso-font-charset:204;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:-520092929 1073786111 9 0 415 0;}
@font-face
	{font-family:"\@Arial Unicode MS";
	panose-1:2 11 6 4 2 2 2 2 2 4;
	mso-font-charset:128;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:-134238209 -371195905 63 0 4129279 0;}
@font-face
	{font-family:"\@MS Mincho";
	panose-1:2 2 6 9 4 2 5 8 3 4;
	mso-font-charset:128;
	mso-generic-font-family:modern;
	mso-font-pitch:fixed;
	mso-font-signature:-536870145 1791491579 18 0 131231 0;}
 /* Style Definitions */
 p.MsoNormal, li.MsoNormal, div.MsoNormal
	{mso-style-unhide:no;
	mso-style-qformat:yes;
	mso-style-parent:"";
	margin-top:0cm;
	margin-right:0cm;
	margin-bottom:8.0pt;
	margin-left:0cm;
	line-height:106%;
	mso-pagination:widow-orphan;
	font-size:11.0pt;
	font-family:"Calibri","sans-serif";
	mso-fareast-font-family:Calibri;
	mso-bidi-font-family:"Times New Roman";
	mso-ansi-language:UK;
	mso-fareast-language:EN-US;}
p.MsoFooter, li.MsoFooter, div.MsoFooter
	{mso-style-priority:99;
	mso-style-link:"Нижний колонтитул Знак";
	margin:0cm;
	margin-bottom:.0001pt;
	mso-pagination:widow-orphan;
	tab-stops:center 240.95pt right 17.0cm;
	font-size:11.0pt;
	font-family:"Calibri","sans-serif";
	mso-fareast-font-family:Calibri;
	mso-bidi-font-family:"Times New Roman";
	mso-ansi-language:UK;
	mso-fareast-language:EN-US;}
span.a
	{mso-style-name:"Нижний колонтитул Знак";
	mso-style-priority:99;
	mso-style-unhide:no;
	mso-style-locked:yes;
	mso-style-parent:"";
	mso-style-link:"Нижний колонтитул";
	font-family:"Calibri","sans-serif";
	mso-ascii-font-family:Calibri;
	mso-fareast-font-family:Calibri;
	mso-hansi-font-family:Calibri;
	mso-bidi-font-family:"Times New Roman";}
.MsoChpDefault
	{mso-style-type:export-only;
	mso-default-props:yes;
	mso-ascii-font-family:Calibri;
	mso-fareast-font-family:Calibri;
	mso-hansi-font-family:Calibri;}
 /* Page Definitions */
 @page
	{mso-footnote-separator:url("UA174580101_B895.files/header.htm") fs;
	mso-footnote-continuation-separator:url("UA174580101_B895.files/header.htm=
") fcs;
	mso-endnote-separator:url("UA174580101_B895.files/header.htm") es;
	mso-endnote-continuation-separator:url("UA174580101_B895.files/header.htm"=
) ecs;}
@page WordSection1
	{size:595.3pt 841.9pt;
	margin:42.5pt 42.5pt 42.5pt 70.85pt;
	mso-header-margin:35.4pt;
	mso-footer-margin:14.0pt;
	mso-footer:url("UA174580101_B895.files/header.htm") f1;
	mso-paper-source:0;}
div.WordSection1
	{page:WordSection1;}
 /* List Definitions */
 @list l0
	{mso-list-id:96944195;
	mso-list-type:hybrid;
	mso-list-template-ids:69389006 -1449991368 69337091 69337093 69337089 6933=
7091 69337093 69337089 69337091 69337093;}
@list l0:level1
	{mso-level-number-format:bullet;
	mso-level-text:\F02D;
	mso-level-tab-stop:0cm;
	mso-level-number-position:left;
	margin-left:0cm;
	text-indent:0cm;
	font-family:Symbol;
	color:windowtext;}
@list l0:level2
	{mso-level-number-format:bullet;
	mso-level-text:o;
	mso-level-tab-stop:72.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:"Courier New";}
@list l0:level3
	{mso-level-number-format:bullet;
	mso-level-text:\F0A7;
	mso-level-tab-stop:108.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:Wingdings;}
@list l0:level4
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:144.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:Symbol;}
@list l0:level5
	{mso-level-number-format:bullet;
	mso-level-text:o;
	mso-level-tab-stop:180.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:"Courier New";}
@list l0:level6
	{mso-level-number-format:bullet;
	mso-level-text:\F0A7;
	mso-level-tab-stop:216.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:Wingdings;}
@list l0:level7
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:252.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:Symbol;}
@list l0:level8
	{mso-level-number-format:bullet;
	mso-level-text:o;
	mso-level-tab-stop:288.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:"Courier New";}
@list l0:level9
	{mso-level-number-format:bullet;
	mso-level-text:\F0A7;
	mso-level-tab-stop:324.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:Wingdings;}
@list l1
	{mso-list-id:1789815855;
	mso-list-type:hybrid;
	mso-list-template-ids:1023203612 -1449991368 536870915 536870917 536870913=
 536870915 536870917 536870913 536870915 536870917;}
@list l1:level1
	{mso-level-number-format:bullet;
	mso-level-text:\F02D;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:54.0pt;
	text-indent:-18.0pt;
	font-family:Symbol;}
@list l1:level2
	{mso-level-number-format:bullet;
	mso-level-text:o;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:90.0pt;
	text-indent:-18.0pt;
	font-family:"Courier New";}
@list l1:level3
	{mso-level-number-format:bullet;
	mso-level-text:\F0A7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:126.0pt;
	text-indent:-18.0pt;
	font-family:Wingdings;}
@list l1:level4
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:162.0pt;
	text-indent:-18.0pt;
	font-family:Symbol;}
@list l1:level5
	{mso-level-number-format:bullet;
	mso-level-text:o;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:198.0pt;
	text-indent:-18.0pt;
	font-family:"Courier New";}
@list l1:level6
	{mso-level-number-format:bullet;
	mso-level-text:\F0A7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:234.0pt;
	text-indent:-18.0pt;
	font-family:Wingdings;}
@list l1:level7
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:270.0pt;
	text-indent:-18.0pt;
	font-family:Symbol;}
@list l1:level8
	{mso-level-number-format:bullet;
	mso-level-text:o;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:306.0pt;
	text-indent:-18.0pt;
	font-family:"Courier New";}
@list l1:level9
	{mso-level-number-format:bullet;
	mso-level-text:\F0A7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:342.0pt;
	text-indent:-18.0pt;
	font-family:Wingdings;}
ol
	{margin-bottom:0cm;}
ul
	{margin-bottom:0cm;}
-->
</style>
<!--[if gte mso 10]>
<style>
 /* Style Definitions */
 table.MsoNormalTable
	{mso-style-name:"Обычная таблица";
	mso-tstyle-rowband-size:0;
	mso-tstyle-colband-size:0;
	mso-style-noshow:yes;
	mso-style-priority:99;
	mso-style-parent:"";
	mso-padding-alt:0cm 5.4pt 0cm 5.4pt;
	mso-para-margin:0cm;
	mso-para-margin-bottom:.0001pt;
	mso-pagination:widow-orphan;
	font-size:10.0pt;
	font-family:"Calibri","sans-serif";
	mso-bidi-font-family:"Times New Roman";}
</style>
<![endif]--><!--[if gte mso 9]><xml>
 <o:shapedefaults v:ext=3D"edit" spidmax=3D"1026"/>
</xml><![endif]--><!--[if gte mso 9]><xml>
 <o:shapelayout v:ext=3D"edit">
  <o:idmap v:ext=3D"edit" data=3D"1"/>
 </o:shapelayout></xml><![endif]-->
</head>

<body lang=3DRU style=3D'tab-interval:35.4pt'>

<div class=3DWordSection1>

<p class=3DMsoNormal align=3Dcenter style=3D'margin-bottom:0cm;margin-botto=
m:.0001pt;
text-align:center;line-height:normal'><b><span lang=3DUK style=3D'font-size=
:12.0pt;
font-family:"Times New Roman","serif";mso-fareast-font-family:"Times New Ro=
man"'>ІНСТРУКЦІЯ<o:p></o:p></span></b></p>

<p class=3DMsoNormal align=3Dcenter style=3D'margin-bottom:0cm;margin-botto=
m:.0001pt;
text-align:center;line-height:normal'><b><span lang=3DUK style=3D'font-size=
:12.0pt;
font-family:"Times New Roman","serif";mso-fareast-font-family:"Times New Ro=
man"'>для
медичного застосування лікарського засобу<o:p></o:p></span></b></p>

<p class=3DMsoNormal align=3Dcenter style=3D'margin-bottom:0cm;margin-botto=
m:.0001pt;
text-align:center;line-height:normal'><b><span lang=3DUK style=3D'font-size=
:12.0pt;
font-family:"Times New Roman","serif";mso-fareast-font-family:"Times New Ro=
man"'><o:p>&nbsp;</o:p></span></b></p>

<p class=3DMsoNormal align=3Dcenter style=3D'margin-bottom:0cm;margin-botto=
m:.0001pt;
text-align:center;line-height:normal'><b><span lang=3DUK style=3D'font-size=
:12.0pt;
font-family:"Times New Roman","serif";mso-fareast-font-family:"Times New Ro=
man"'>ІТОПРИД</span></b><b><span
style=3D'font-size:12.0pt;font-family:"Times New Roman","serif";mso-fareast=
-font-family:
"Times New Roman";mso-ansi-language:RU'>-ФАРМАК</span></b><b><sup><span
lang=3DUK style=3D'font-size:12.0pt;font-family:"Times New Roman","serif";
mso-fareast-font-family:"Times New Roman"'><o:p></o:p></span></sup></b></p>

<p class=3DMsoNormal align=3Dcenter style=3D'margin-bottom:0cm;margin-botto=
m:.0001pt;
text-align:center;line-height:normal'><b><span lang=3DUK style=3D'font-size=
:12.0pt;
font-family:"Times New Roman","serif";mso-fareast-font-family:"Times New Ro=
man"'>(ITOPRID</span></b><b><span
style=3D'font-size:12.0pt;font-family:"Times New Roman","serif";mso-fareast=
-font-family:
"Times New Roman";mso-ansi-language:RU'>-</span></b><b><span lang=3DEN-US
style=3D'font-size:12.0pt;font-family:"Times New Roman","serif";mso-fareast=
-font-family:
"Times New Roman";mso-ansi-language:EN-US'>FARMAK</span></b><b><span lang=
=3DUK
style=3D'font-size:12.0pt;font-family:"Times New Roman","serif";mso-fareast=
-font-family:
"Times New Roman"'>)<o:p></o:p></span></b></p>

<p class=3DMsoNormal align=3Dcenter style=3D'margin-bottom:0cm;margin-botto=
m:.0001pt;
text-align:center;line-height:normal'><span lang=3DUK style=3D'font-size:12=
.0pt;
font-family:"Times New Roman","serif";mso-fareast-font-family:"Arial Unicod=
e MS"'><o:p>&nbsp;</o:p></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal'><b><i><span lang=3DUK style=3D'font-size:12.0pt;
font-family:"Times New Roman","serif";mso-fareast-font-family:"Times New Ro=
man"'>Склад:</span></i></b><i><span
lang=3DUK style=3D'font-size:12.0pt;font-family:"Times New Roman","serif";
mso-fareast-font-family:"Times New Roman"'><o:p></o:p></span></i></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal'><i><span lang=3DUK style=3D'font-size:12.0pt;
font-family:"Times New Roman","serif";mso-fareast-font-family:"Arial Unicod=
e MS"'>діюча
речовина:</span></i><span lang=3DUK style=3D'font-size:12.0pt;font-family:"=
Times New Roman","serif";
mso-fareast-font-family:"Arial Unicode MS"'> ітоприду гідрохлорид;<o:p></o:=
p></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal'><span lang=3DUK style=3D'font-size:12.0pt;font-=
family:
"Times New Roman","serif";mso-fareast-font-family:"Times New Roman"'>1</spa=
n><span
lang=3DUK style=3D'font-size:12.0pt;font-family:"Times New Roman","serif";
mso-fareast-font-family:"Arial Unicode MS"'> таблетка містить 50 мг ітоприду
гідрохлориду;<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal;tab-stops:15.6pt;mso-layout-grid-align:none'><i
style=3D'mso-bidi-font-style:normal'><span lang=3DUK style=3D'font-size:12.=
0pt;
font-family:"Times New Roman","serif";mso-fareast-font-family:"Times New Ro=
man"'>допоміжні
речовини: </span></i><span lang=3DUK style=3D'font-size:12.0pt;font-family:=
"Times New Roman","serif";
mso-fareast-font-family:"Times New Roman"'>лактоза, моногідрат; крохмаль
прежелатинізований; натрію кроскармелоза; кремнію діоксид колоїдний безводн=
ий; магнію
стеарат.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal;tab-stops:15.6pt;mso-layout-grid-align:none'><sp=
an
lang=3DUK style=3D'font-size:12.0pt;font-family:"Times New Roman","serif";
mso-fareast-font-family:"Times New Roman"'><span
style=3D'mso-spacerun:yes'> </span><o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal'><b><span lang=3DUK style=3D'font-size:12.0pt;
font-family:"Times New Roman","serif";mso-fareast-font-family:"Arial Unicod=
e MS"'>Лікарська
форма.</span></b><span lang=3DUK style=3D'font-size:12.0pt;font-family:"Tim=
es New Roman","serif";
mso-fareast-font-family:"Arial Unicode MS"'> Таблетки.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal'><i style=3D'mso-bidi-font-style:normal'><span
lang=3DUK style=3D'font-size:12.0pt;font-family:"Times New Roman","serif";
mso-fareast-font-family:"Times New Roman"'>Основні фізико-хімічні властивос=
ті:<b
style=3D'mso-bidi-font-weight:normal'> </b></span></i><span lang=3DUK
style=3D'font-size:12.0pt;font-family:"Times New Roman","serif";mso-fareast=
-font-family:
"Times New Roman"'>таблетки білого або майже білого кольору, круглої форми,
двоопуклі, з рискою з одного боку. Таблетка може бути поділена на рівні доз=
и.<b
style=3D'mso-bidi-font-weight:normal'><i style=3D'mso-bidi-font-style:norma=
l'><o:p></o:p></i></b></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal'><span lang=3DUK style=3D'font-size:12.0pt;font-=
family:
"Times New Roman","serif";mso-fareast-font-family:"Arial Unicode MS"'><o:p>=
&nbsp;</o:p></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal'><b style=3D'mso-bidi-font-weight:normal'><span
lang=3DUK style=3D'font-size:12.0pt;font-family:"Times New Roman","serif";
mso-fareast-font-family:"Times New Roman"'>Фармакотерапевтична група. </spa=
n></b><span
lang=3DUK style=3D'font-size:12.0pt;font-family:"Times New Roman","serif";
mso-fareast-font-family:"Times New Roman";letter-spacing:-.3pt'>Стимулятори
перистальтики</span><span lang=3DUK style=3D'font-size:12.0pt;font-family:"=
Times New Roman","serif";
mso-fareast-font-family:"Times New Roman"'>. </span><span lang=3DUK
style=3D'font-size:12.0pt;font-family:"Times New Roman","serif";mso-fareast=
-font-family:
"Arial Unicode MS"'>Код АТX А03F A07.</span><b style=3D'mso-bidi-font-weigh=
t:
normal'><span lang=3DUK style=3D'font-size:12.0pt;font-family:"Times New Ro=
man","serif";
mso-fareast-font-family:"Times New Roman"'><o:p></o:p></span></b></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal;page-break-after:avoid;mso-outline-level:1'><b><=
span
lang=3DUK style=3D'font-size:12.0pt;font-family:"Times New Roman","serif";
mso-fareast-font-family:"Times New Roman"'><o:p>&nbsp;</o:p></span></b></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal;page-break-after:avoid;mso-outline-level:1'><b><i
style=3D'mso-bidi-font-style:normal'><span lang=3DUK style=3D'font-size:12.=
0pt;
font-family:"Times New Roman","serif";mso-fareast-font-family:"Times New Ro=
man"'>Фармакологічні
властивості.<o:p></o:p></span></i></b></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal'><i><span lang=3DUK style=3D'font-size:12.0pt;
font-family:"Times New Roman","serif";mso-fareast-font-family:"Times New Ro=
man";
mso-bidi-font-weight:bold'>Фармакодинаміка.</span></i><span lang=3DUK
style=3D'font-size:12.0pt;font-family:"Times New Roman","serif";mso-fareast=
-font-family:
"Times New Roman";mso-bidi-font-weight:bold'> <o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal'><span lang=3DUK style=3D'font-size:12.0pt;font-=
family:
"Times New Roman","serif";mso-fareast-font-family:"Times New Roman";letter-=
spacing:
.2pt'>Ітоприду гідрохлорид активує пропульсивну моторику шлунково-кишкового
тракту завдяки антагонізму з допаміновими D<sub>2</sub>-рецепторами та
інгібуючій активності ацетилхолінестерази. Ітоприду гідрохлорид активує
вивільнення ацетилхоліну та інгібує його розпад. Ітоприду гідрохлорид також
чинить протиблювальну дію завдяки взаємодії з D<sub>2</sub>-рецепторами,
локалізованими в хеморецепторній тригерній зоні, що було продемонстровано д=
озозалежним
інгібуванням апоморфініндукованого блювання у тварин. Дія ітоприду гідрохло=
риду
є високоспецифічною відносно верхніх відділів шлунково-кишкового тракту. <o=
:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal'><span lang=3DUK style=3D'font-size:12.0pt;font-=
family:
"Times New Roman","serif";mso-fareast-font-family:"Times New Roman";letter-=
spacing:
.2pt'>Ітоприду гідрохлорид не впливає на рівень гастрину в сироватці крові.=
<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal'><i><span lang=3DUK style=3D'font-size:12.0pt;
font-family:"Times New Roman","serif";mso-fareast-font-family:"Times New Ro=
man";
letter-spacing:.1pt;mso-bidi-font-weight:bold'>Фармакокінетика. <o:p></o:p>=
</span></i></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal'><i style=3D'mso-bidi-font-style:normal'><span
lang=3DUK style=3D'font-size:12.0pt;font-family:"Times New Roman","serif";
mso-fareast-font-family:"Times New Roman";mso-bidi-font-weight:bold'>Абсорб=
ція.</span></i><span
lang=3DUK style=3D'font-size:12.0pt;font-family:"Times New Roman","serif";
mso-fareast-font-family:"Times New Roman";mso-bidi-font-weight:bold'> Ітопр=
иду
гідрохлорид швидко та практично повністю всмоктується зі шлунково-кишкового
тракту. Його відносна біодоступність становить 60 %, що пов’язано з ефектом
«першого проходження» через печінку. Їжа не впливає на біодоступність. Після
застосування 50 мг ітоприду гідрохлориду С<sub>max</sub> досягається через =
0,5 </span><span
lang=3DUK style=3D'font-size:12.0pt;font-family:"Times New Roman","serif";
mso-fareast-font-family:"Arial Unicode MS"'>– </span><span lang=3DUK
style=3D'font-size:12.0pt;font-family:"Times New Roman","serif";mso-fareast=
-font-family:
"Times New Roman";mso-bidi-font-weight:bold'>0,75 години та становить 0,28
мкг/мл. При подальшому застосуванні лікарського засобу в дозах від 50 до 20=
0 мг
3 рази на добу впродовж 7 днів фармакокінетика ітоприду гідрохлориду та його
метаболітів була лінійною з мінімальною кумуляцією. <o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal'><i style=3D'mso-bidi-font-style:normal'><span
lang=3DUK style=3D'font-size:12.0pt;font-family:"Times New Roman","serif";
mso-fareast-font-family:"Times New Roman";mso-bidi-font-weight:bold'>Розпод=
іл.</span></i><span
lang=3DUK style=3D'font-size:12.0pt;font-family:"Times New Roman","serif";
mso-fareast-font-family:"Times New Roman";mso-bidi-font-weight:bold'> Прибл=
изно
96 % ітоприду гідрохлориду зв’язується з білками плазми (переважно з
альбуміном). Зв’язування з &#945;<sub>1</sub>-кислим глікопротеїном станови=
ть
менше 15 %.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal'><i style=3D'mso-bidi-font-style:normal'><span
lang=3DUK style=3D'font-size:12.0pt;font-family:"Times New Roman","serif";
mso-fareast-font-family:"Times New Roman";mso-bidi-font-weight:bold'>Метабо=
лізм.</span></i><span
lang=3DUK style=3D'font-size:12.0pt;font-family:"Times New Roman","serif";
mso-fareast-font-family:"Times New Roman";mso-bidi-font-weight:bold'> Ітопр=
иду
гідрохлорид активно біотрансформується у печінці. Ідентифіковано
3&nbsp;метаболіти, тільки один з яких проявляє незначну активність, що не м=
ає
фармакологічного значення (приблизно 2 </span><span lang=3DUK style=3D'font=
-size:
12.0pt;font-family:"Times New Roman","serif";mso-fareast-font-family:"Arial=
 Unicode MS"'>–
</span><span lang=3DUK style=3D'font-size:12.0pt;font-family:"Times New Rom=
an","serif";
mso-fareast-font-family:"Times New Roman";mso-bidi-font-weight:bold'>3 %
ітоприду гідрохлориду). Первинним метаболітом є N-оксид, що утворюється у
результаті окиснення четвертинної аміно-N-диметильної групи. <o:p></o:p></s=
pan></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal'><span lang=3DUK style=3D'font-size:12.0pt;font-=
family:
"Times New Roman","serif";mso-fareast-font-family:"Times New Roman";mso-bid=
i-font-weight:
bold'>Ітоприду гідрохлорид метаболізується під дією флавінзалежної
монооксигенази (FMO3). Кількість та ефективність ізоферментів FMO у людини =
може
відрізнятися залежно від генетичного поліморфізму, який інколи призводить до
розвитку аутосомно-рецесивного стану, відомого під назвою триметиламінурія
(синдром «рибного запаху»). У пацієнтів, хворих на триметиламінурію, Т<sub>=
1/2 </sub>збільшується.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal'><span lang=3DUK style=3D'font-size:12.0pt;font-=
family:
"Times New Roman","serif";mso-fareast-font-family:"Times New Roman";mso-bid=
i-font-weight:
bold'>Згідно з даними фармакокінетичних досліджень <i style=3D'mso-bidi-fon=
t-style:
normal'>in vivo</i> ітоприду гідрохлорид не чинить інгібуючої або індукуючої
дії відносно CYP2C19 та CYP2E1. Застосування ітоприду гідрохлориду не вплив=
ає
на вміст CYP або активність уридиндифосфатглюкуронізил­трансферази.<o:p></o=
:p></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal'><i style=3D'mso-bidi-font-style:normal'><span
lang=3DUK style=3D'font-size:12.0pt;font-family:"Times New Roman","serif";
mso-fareast-font-family:"Times New Roman";mso-bidi-font-weight:bold'>Виведе=
ння.</span></i><span
lang=3DUK style=3D'font-size:12.0pt;font-family:"Times New Roman","serif";
mso-fareast-font-family:"Times New Roman";mso-bidi-font-weight:bold'> Ітопр=
иду
гідрохлорид та його метаболіти виводяться переважно з сечею. Ниркова екскре=
ція ітоприду
гідрохлориду та його N-оксиду становила 3,7 % та 75,4 % відповідно після
одноразового внутрішнього застосування лікарського засобу здоровим добровол=
ьцям
у терапевтичній дозі. <o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal'><span lang=3DUK style=3D'font-size:12.0pt;font-=
family:
"Times New Roman","serif";mso-fareast-font-family:"Times New Roman";mso-bid=
i-font-weight:
bold'>Термінальний Т<sub>1/2 </sub>ітоприду гідрохлориду становив приблизно=
 6
годин.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal'><b><span lang=3DUK style=3D'font-size:12.0pt;
font-family:"Times New Roman","serif";mso-fareast-font-family:"Times New Ro=
man"'><o:p>&nbsp;</o:p></span></b></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal'><b><span lang=3DUK style=3D'font-size:12.0pt;
font-family:"Times New Roman","serif";mso-fareast-font-family:"Times New Ro=
man"'>Клінічні
характеристики. </span></b><span lang=3DUK style=3D'font-size:12.0pt;font-f=
amily:
"Times New Roman","serif";mso-fareast-font-family:"Times New Roman"'><o:p><=
/o:p></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal;page-break-after:avoid;mso-outline-level:1'><b><=
i><span
lang=3DUK style=3D'font-size:12.0pt;font-family:"Times New Roman","serif";
mso-fareast-font-family:"Times New Roman"'>Показання. <o:p></o:p></span></i=
></b></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal'><span lang=3DUK style=3D'font-size:12.0pt;font-=
family:
"Times New Roman","serif";mso-fareast-font-family:"Times New Roman"'>Купіру=
вання
шлунково-кишкових симптомів функціональної невиразкової диспепсії (хронічно=
го
гастриту), а саме: <o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-top:0cm;margin-right:0cm;margin-bottom=
:0cm;
margin-left:21.3pt;margin-bottom:.0001pt;text-align:justify;text-indent:-18=
.0pt;
line-height:normal;mso-list:l1 level1 lfo1'><![if !supportLists]><span lang=
=3DUK
style=3D'font-size:12.0pt;font-family:Symbol;mso-fareast-font-family:Symbol;
mso-bidi-font-family:Symbol'><span style=3D'mso-list:Ignore'>-<span
style=3D'font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;=
&nbsp;
</span></span></span><![endif]><span lang=3DUK style=3D'font-size:12.0pt;
font-family:"Times New Roman","serif";mso-fareast-font-family:"Times New Ro=
man"'>здуття
живота; <o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-top:0cm;margin-right:0cm;margin-bottom=
:0cm;
margin-left:21.3pt;margin-bottom:.0001pt;text-align:justify;text-indent:-18=
.0pt;
line-height:normal;mso-list:l1 level1 lfo1'><![if !supportLists]><span lang=
=3DUK
style=3D'font-size:12.0pt;font-family:Symbol;mso-fareast-font-family:Symbol;
mso-bidi-font-family:Symbol'><span style=3D'mso-list:Ignore'>-<span
style=3D'font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;=
&nbsp;
</span></span></span><![endif]><span lang=3DUK style=3D'font-size:12.0pt;
font-family:"Times New Roman","serif";mso-fareast-font-family:"Times New Ro=
man"'>відчуття
швидкого насичення; <o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-top:0cm;margin-right:0cm;margin-bottom=
:0cm;
margin-left:21.3pt;margin-bottom:.0001pt;text-align:justify;text-indent:-18=
.0pt;
line-height:normal;mso-list:l1 level1 lfo1'><![if !supportLists]><span lang=
=3DUK
style=3D'font-size:12.0pt;font-family:Symbol;mso-fareast-font-family:Symbol;
mso-bidi-font-family:Symbol'><span style=3D'mso-list:Ignore'>-<span
style=3D'font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;=
&nbsp;
</span></span></span><![endif]><span lang=3DUK style=3D'font-size:12.0pt;
font-family:"Times New Roman","serif";mso-fareast-font-family:"Times New Ro=
man"'>біль
та дискомфорт у верхній частині живота; <o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-top:0cm;margin-right:0cm;margin-bottom=
:0cm;
margin-left:21.3pt;margin-bottom:.0001pt;text-align:justify;text-indent:-18=
.0pt;
line-height:normal;mso-list:l1 level1 lfo1'><![if !supportLists]><span lang=
=3DUK
style=3D'font-size:12.0pt;font-family:Symbol;mso-fareast-font-family:Symbol;
mso-bidi-font-family:Symbol'><span style=3D'mso-list:Ignore'>-<span
style=3D'font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;=
&nbsp;
</span></span></span><![endif]><span lang=3DUK style=3D'font-size:12.0pt;
font-family:"Times New Roman","serif";mso-fareast-font-family:"Times New Ro=
man"'>анорексія;
<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-top:0cm;margin-right:0cm;margin-bottom=
:0cm;
margin-left:21.3pt;margin-bottom:.0001pt;text-align:justify;text-indent:-18=
.0pt;
line-height:normal;mso-list:l1 level1 lfo1'><![if !supportLists]><span lang=
=3DUK
style=3D'font-size:12.0pt;font-family:Symbol;mso-fareast-font-family:Symbol;
mso-bidi-font-family:Symbol'><span style=3D'mso-list:Ignore'>-<span
style=3D'font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;=
&nbsp;
</span></span></span><![endif]><span lang=3DUK style=3D'font-size:12.0pt;
font-family:"Times New Roman","serif";mso-fareast-font-family:"Times New Ro=
man"'>печія;<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-top:0cm;margin-right:0cm;margin-bottom=
:0cm;
margin-left:21.3pt;margin-bottom:.0001pt;text-align:justify;text-indent:-18=
.0pt;
line-height:normal;mso-list:l1 level1 lfo1'><![if !supportLists]><span lang=
=3DUK
style=3D'font-size:12.0pt;font-family:Symbol;mso-fareast-font-family:Symbol;
mso-bidi-font-family:Symbol'><span style=3D'mso-list:Ignore'>-<span
style=3D'font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;=
&nbsp;
</span></span></span><![endif]><span lang=3DUK style=3D'font-size:12.0pt;
font-family:"Times New Roman","serif";mso-fareast-font-family:"Times New Ro=
man"'>нудота;
<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-top:0cm;margin-right:0cm;margin-bottom=
:0cm;
margin-left:21.3pt;margin-bottom:.0001pt;text-align:justify;text-indent:-18=
.0pt;
line-height:normal;mso-list:l1 level1 lfo1'><![if !supportLists]><span lang=
=3DUK
style=3D'font-size:12.0pt;font-family:Symbol;mso-fareast-font-family:Symbol;
mso-bidi-font-family:Symbol'><span style=3D'mso-list:Ignore'>-<span
style=3D'font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;=
&nbsp;
</span></span></span><![endif]><span lang=3DUK style=3D'font-size:12.0pt;
font-family:"Times New Roman","serif";mso-fareast-font-family:"Times New Ro=
man"'>блювання.
<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal'><b style=3D'mso-bidi-font-weight:normal'><i
style=3D'mso-bidi-font-style:normal'><span lang=3DUK style=3D'font-size:12.=
0pt;
font-family:"Times New Roman","serif";mso-fareast-font-family:"Times New Ro=
man"'><o:p>&nbsp;</o:p></span></i></b></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal'><b style=3D'mso-bidi-font-weight:normal'><i
style=3D'mso-bidi-font-style:normal'><span lang=3DUK style=3D'font-size:12.=
0pt;
font-family:"Times New Roman","serif";mso-fareast-font-family:"Times New Ro=
man"'>Протипоказання.
<o:p></o:p></span></i></b></p>

<p class=3DMsoNormal style=3D'margin:0cm;margin-bottom:.0001pt;text-align:j=
ustify;
text-indent:0cm;line-height:normal;mso-list:l0 level1 lfo2;tab-stops:list 2=
1.3pt'><![if !supportLists]><span
lang=3DUK style=3D'font-size:12.0pt;font-family:Symbol;mso-fareast-font-fam=
ily:
Symbol;mso-bidi-font-family:Symbol'><span style=3D'mso-list:Ignore'>-<span
style=3D'font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;=
&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=3DUK style=3D'font-size:12.0pt;
font-family:"Times New Roman","serif";mso-fareast-font-family:"Times New Ro=
man"'>Підвищена
чутливість до ітоприду гідрохлориду та до інших компонентів препарату.<o:p>=
</o:p></span></p>

<p class=3DMsoNormal style=3D'margin:0cm;margin-bottom:.0001pt;text-align:j=
ustify;
text-indent:0cm;line-height:normal;mso-list:l0 level1 lfo2;tab-stops:list 2=
1.3pt'><![if !supportLists]><span
lang=3DUK style=3D'font-size:12.0pt;font-family:Symbol;mso-fareast-font-fam=
ily:
Symbol;mso-bidi-font-family:Symbol;letter-spacing:.05pt'><span
style=3D'mso-list:Ignore'>-<span style=3D'font:7.0pt "Times New Roman"'>&nb=
sp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=3DUK style=3D'font-size:12.0pt;
font-family:"Times New Roman","serif";mso-fareast-font-family:"Times New Ro=
man"'>Стани,
при яких підвищення скорочувальної активності шлунково-кишкового тракту може
бути шкідливим, наприклад при шлунково-кишковій кровотечі, механічній
обструкції або перфорації. <span style=3D'letter-spacing:.05pt'><o:p></o:p>=
</span></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal'><span lang=3DUK style=3D'font-size:12.0pt;font-=
family:
"Times New Roman","serif";mso-fareast-font-family:"Times New Roman";letter-=
spacing:
.05pt'><o:p>&nbsp;</o:p></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal;page-break-after:avoid;mso-outline-level:1'><b><=
i><span
lang=3DUK style=3D'font-size:12.0pt;font-family:"Times New Roman","serif";
mso-fareast-font-family:"Times New Roman"'>Взаємодія з іншими лікарськими
засобами та інші види взаємодій.<o:p></o:p></span></i></b></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal'><span lang=3DUK style=3D'font-size:12.0pt;font-=
family:
"Times New Roman","serif";mso-fareast-font-family:"Times New Roman"'>Метабо=
лічні
взаємодії не очікуються у зв’язку з тим, що ітоприду гідрохлорид первинно
метаболізується флавінмонооксигеназою, а не ізоферментами системи цитохрому
Р450. <o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal'><span lang=3DUK style=3D'font-size:12.0pt;font-=
family:
"Times New Roman","serif";mso-fareast-font-family:"Times New Roman"'>Ніяких
змін щодо зв’язування з білками при одночасному застосуванні з варфарином,
діазепамом, диклофенаком натрію, тиклопідину гідрохлоридом, ніфедипіном та
нікардипіну гідрохлоридом не спостерігалося. У зв’язку з тим, що ітоприду
гідрохлорид має гастрокінетичний ефект, він може впливати на всмоктування і=
нших
лікарських засобів, що застосовуються одночасно перорально. <o:p></o:p></sp=
an></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal'><span lang=3DUK style=3D'font-size:12.0pt;font-=
family:
"Times New Roman","serif";mso-fareast-font-family:"Times New Roman"'>З
особливою обережністю слід застосовувати лікарські засоби з вузьким
терапевтичним індексом, уповільненим вивільненням або з кишковорозчинною
оболонкою.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal'><span lang=3DUK style=3D'font-size:12.0pt;font-=
family:
"Times New Roman","serif";mso-fareast-font-family:"Times New Roman"'>Против=
иразкові
лікарські засоби, такі як циметидин, ранітидин, тепренон та цетраксат, не
впливають на прокінетичну дію ітоприду гідрохлориду. <o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal'><span lang=3DUK style=3D'font-size:12.0pt;font-=
family:
"Times New Roman","serif";mso-fareast-font-family:"Times New Roman"'>Антихо=
лінергічні
лікарські засоби можуть знижувати дію ітоприду гідрохлориду.<span
style=3D'letter-spacing:.05pt'><o:p></o:p></span></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal'><b style=3D'mso-bidi-font-weight:normal'><i
style=3D'mso-bidi-font-style:normal'><span lang=3DUK style=3D'font-size:12.=
0pt;
font-family:"Times New Roman","serif";mso-fareast-font-family:"Times New Ro=
man"'><o:p>&nbsp;</o:p></span></i></b></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal'><b style=3D'mso-bidi-font-weight:normal'><i><sp=
an
lang=3DUK style=3D'font-size:12.0pt;font-family:"Times New Roman","serif";
mso-fareast-font-family:"Times New Roman"'>Особливості застосування.<o:p></=
o:p></span></i></b></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal'><span lang=3DUK style=3D'font-size:12.0pt;font-=
family:
"Times New Roman","serif";mso-fareast-font-family:"Times New Roman";mso-bid=
i-font-style:
italic'>Ітоприду гідрохлорид посилює дію ацетилхоліну та може призвести до
холінергічних побічних ефектів. Дані про довготривале застосування відсутні=
.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal'><span lang=3DUK style=3D'font-size:12.0pt;font-=
family:
"Times New Roman","serif";mso-fareast-font-family:"Times New Roman";mso-bid=
i-font-style:
italic'>Загалом, ітоприду гідрохлорид пацієнтам літнього віку слід признача=
ти з
доцільною обережністю та подальшим спостереженням, враховуючи підвищену час=
тоту
погіршеної функції нирок, печінки, супутніх захворювань або супутню терапію
іншими лікарськими засобами у таких пацієнтів.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal;page-break-after:avoid;mso-outline-level:4;
tab-stops:467.75pt'><i style=3D'mso-bidi-font-style:normal'><span lang=3DUK
style=3D'font-size:12.0pt;font-family:"Times New Roman","serif";mso-fareast=
-font-family:
"Times New Roman"'><o:p>&nbsp;</o:p></span></i></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal;page-break-after:avoid;mso-outline-level:4;
tab-stops:467.75pt'><i style=3D'mso-bidi-font-style:normal'><span lang=3DUK
style=3D'font-size:12.0pt;font-family:"Times New Roman","serif";mso-fareast=
-font-family:
"Times New Roman"'>Застосування у період вагітності або годування груддю. <=
o:p></o:p></span></i></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal'><i style=3D'mso-bidi-font-style:normal'><span
lang=3DUK style=3D'font-size:12.0pt;font-family:"Times New Roman","serif";
mso-fareast-font-family:"Times New Roman"'>Вагітність<o:p></o:p></span></i>=
</p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal'><span lang=3DUK style=3D'font-size:12.0pt;font-=
family:
"Times New Roman","serif";mso-fareast-font-family:"Times New Roman"'>Дані п=
ро
застосування ітоприду вагітним жінкам відсутні або обмежені (менше 300 випа=
дків
результатів вагітності). Дослідження на тваринах не виявили ніякого прямого=
 або
непрямого шкідливого токсичного ефекту на репродуктивну функцію. Як<span
style=3D'mso-spacerun:yes'>  </span>профілактичний захід бажано відмовитися=
 від
застосування ітоприду у період вагітності.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal'><i style=3D'mso-bidi-font-style:normal'><span
lang=3DUK style=3D'font-size:12.0pt;font-family:"Times New Roman","serif";
mso-fareast-font-family:"Times New Roman"'>Годування груддю<o:p></o:p></spa=
n></i></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal'><span lang=3DUK style=3D'font-size:12.0pt;font-=
family:
"Times New Roman","serif";mso-fareast-font-family:"Times New Roman"'>Ітоприд
проникає у грудне молоко тварин, але щодо проникнення ітоприду у грудне
молоко<span style=3D'mso-spacerun:yes'>  </span>людини даних недостатньо. Р=
изик
для дитини, що знаходиться на грудному годуванні, не може бути виключений.
Рішення про припинення грудного вигодовування або припинення/ призупинення
прийому ітоприду слід приймати з огляду на користь грудного вигодовування д=
ля
дитини і користь лікування для жінки.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal'><i style=3D'mso-bidi-font-style:normal'><span
lang=3DUK style=3D'font-size:12.0pt;font-family:"Times New Roman","serif";
mso-fareast-font-family:"Times New Roman"'>Фертильність<o:p></o:p></span></=
i></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal'><span lang=3DUK style=3D'font-size:12.0pt;font-=
family:
"Times New Roman","serif";mso-fareast-font-family:"Times New Roman"'>Даних =
щодо
впливу ітоприду на фертильність людини немає; однак дослідження на тваринах=
 не
виявили шкідливого впливу ітоприду.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal'><span lang=3DUK style=3D'font-size:12.0pt;font-=
family:
"Times New Roman","serif";mso-fareast-font-family:"Arial Unicode MS"'><o:p>=
&nbsp;</o:p></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal;page-break-after:avoid;mso-outline-level:4;
tab-stops:467.75pt'><i style=3D'mso-bidi-font-style:normal'><span lang=3DUK
style=3D'font-size:12.0pt;font-family:"Times New Roman","serif";mso-fareast=
-font-family:
"Times New Roman"'>Здатність впливати на швидкість реакції при керуванні
автотранспортом або іншими механізмами. <o:p></o:p></span></i></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal'><span lang=3DUK style=3D'font-size:12.0pt;font-=
family:
"Times New Roman","serif";mso-fareast-font-family:"Times New Roman";mso-far=
east-language:
RU;mso-bidi-font-weight:bold;mso-bidi-font-style:italic'>Інформація щодо
можливого впливу на швидкість реакції відсутня, але під час вирішення питан=
ня
щодо керування автотранспортом або роботи з іншими механізмами необхідно
врахувати можливість виникнення запаморочення. <o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal'><b style=3D'mso-bidi-font-weight:normal'><i
style=3D'mso-bidi-font-style:normal'><span lang=3DUK style=3D'font-size:12.=
0pt;
font-family:"Times New Roman","serif";mso-fareast-font-family:"Times New Ro=
man"'><o:p>&nbsp;</o:p></span></i></b></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal;page-break-after:avoid;mso-outline-level:3'><b><=
i><span
lang=3DUK style=3D'font-size:12.0pt;font-family:"Times New Roman","serif";
mso-fareast-font-family:"Times New Roman"'>Спосіб застосування та дози.<o:p=
></o:p></span></i></b></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal'><span lang=3DUK style=3D'font-size:12.0pt;font-=
family:
"Times New Roman","serif";mso-fareast-font-family:"Times New Roman"'>Для
дорослих рекомендована доза становить 150 мг на добу (по 1 таблетці (50 мг)=
 3
рази на добу перед прийомом їжі). Зазначена доза може бути знижена з
урахуванням віку пацієнта та симптомів (див. «Особливості застосування»).<o=
:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal'><span lang=3DUK style=3D'font-size:12.0pt;font-=
family:
"Times New Roman","serif";mso-fareast-font-family:"Times New Roman"'>Під час
клінічних досліджень тривалість застосування ітоприду гідрохлориду становил=
а до
8&nbsp;тижнів.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal'><b style=3D'mso-bidi-font-weight:normal'><i><sp=
an
lang=3DUK style=3D'font-size:12.0pt;font-family:"Times New Roman","serif";
mso-fareast-font-family:"Times New Roman"'><o:p>&nbsp;</o:p></span></i></b>=
</p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal'><i><span lang=3DUK style=3D'font-size:12.0pt;
font-family:"Times New Roman","serif";mso-fareast-font-family:"Times New Ro=
man"'>Діти.<b
style=3D'mso-bidi-font-weight:normal'> </b></span></i><span lang=3DUK
style=3D'font-size:12.0pt;font-family:"Times New Roman","serif";mso-fareast=
-font-family:
"Arial Unicode MS"'><o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal'><span lang=3DUK style=3D'font-size:12.0pt;font-=
family:
"Times New Roman","serif";mso-fareast-font-family:"Arial Unicode MS"'>Безпе=
ка
застосування ітоприду гідрохлориду дітям віком до 16 років не встановлена.<=
o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal;page-break-after:avoid;mso-outline-level:1'><b><=
i><span
lang=3DUK style=3D'font-size:12.0pt;font-family:"Times New Roman","serif";
mso-fareast-font-family:"Times New Roman"'><o:p>&nbsp;</o:p></span></i></b>=
</p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal;page-break-after:avoid;mso-outline-level:1'><b><=
i><span
lang=3DUK style=3D'font-size:12.0pt;font-family:"Times New Roman","serif";
mso-fareast-font-family:"Times New Roman"'>Передозування. <o:p></o:p></span=
></i></b></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal;page-break-after:avoid;mso-outline-level:4;
tab-stops:467.75pt'><i style=3D'mso-bidi-font-style:normal'><span lang=3DUK
style=3D'font-size:12.0pt;font-family:"Times New Roman","serif";mso-fareast=
-font-family:
"Arial Unicode MS"'>Лікування. </span></i><span lang=3DUK style=3D'font-siz=
e:12.0pt;
font-family:"Times New Roman","serif";mso-fareast-font-family:"Arial Unicod=
e MS"'>У
разі надмірного передозування необхідно вжити звичайних заходів щодо промив=
ання
шлунка та провести симптоматичне лікування. <o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal;page-break-after:avoid;mso-outline-level:1'><b><=
i><span
lang=3DUK style=3D'font-size:12.0pt;font-family:"Times New Roman","serif";
mso-fareast-font-family:"Times New Roman"'><o:p>&nbsp;</o:p></span></i></b>=
</p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal;page-break-after:avoid;mso-outline-level:1'><b><=
i><span
lang=3DUK style=3D'font-size:12.0pt;font-family:"Times New Roman","serif";
mso-fareast-font-family:"Times New Roman"'>Побічні реакції.<o:p></o:p></spa=
n></i></b></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal'><span lang=3DUK style=3D'font-size:12.0pt;font-=
family:
"Times New Roman","serif";mso-fareast-font-family:"Times New Roman";mso-far=
east-language:
UK'>Нижченаведені</span><span lang=3DUK style=3D'font-size:12.0pt;font-fami=
ly:"Times New Roman","serif";
mso-fareast-font-family:"Times New Roman"'> побічні реакції спостерігалися з
наведеною частотою у 998 пацієнтів, які отримували ітоприд у 4 клінічних
плацебо-контрольованих дослідженнях, 4 клінічних порівняльних дослідженнях =
і 13
неконтрольованих інтервенційних клінічних дослідженнях зі стандартною добов=
ою
дозою ітоприду 150 мг або менше. </span><span lang=3DUK style=3D'font-size:=
12.0pt;
font-family:"Times New Roman","serif";mso-fareast-font-family:"Times New Ro=
man";
mso-fareast-language:UK'>Побічні реакції класифіковано за системами органів
(згідно з MedDRA) та за частотою виникнення: </span><span lang=3DUK
style=3D'font-size:12.0pt;font-family:"Times New Roman","serif";mso-fareast=
-font-family:
"Times New Roman"'>часто ( від&gt; 1/100 до &lt;1/10) і нечасто (від&gt; 1/=
1000
до &lt;1/100). У категоріях «дуже часто» (&gt; 1/10), «рідко» (від&gt; 1/10=
000
до &lt;1/1000) та «дуже рідко» (&lt;1/10000) побічних реакцій не виявлено.<=
o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal'><i style=3D'mso-bidi-font-style:normal'><span
lang=3DUK style=3D'font-size:12.0pt;font-family:"Times New Roman","serif";
mso-fareast-font-family:"Times New Roman";mso-fareast-language:UK'>Шлунково=
-кишкові
розлади: </span></i><span lang=3DUK style=3D'font-size:12.0pt;font-family:"=
Times New Roman","serif";
mso-fareast-font-family:"Times New Roman"'>часто </span><span lang=3DUK
style=3D'font-size:12.0pt;font-family:"Times New Roman","serif";mso-fareast=
-font-family:
"Arial Unicode MS"'>–</span><span lang=3DUK style=3D'font-size:12.0pt;font-=
family:
"Times New Roman","serif";mso-fareast-font-family:"Times New Roman"'> біль у
животі, діарея; нечасто </span><span lang=3DUK style=3D'font-size:12.0pt;
font-family:"Times New Roman","serif";mso-fareast-font-family:"Arial Unicod=
e MS"'>–</span><span
lang=3DUK style=3D'font-size:12.0pt;font-family:"Times New Roman","serif";
mso-fareast-font-family:"Times New Roman"'> підвищене слиновиділення.<o:p><=
/o:p></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal;tab-stops:402.55pt'><i style=3D'mso-bidi-font-st=
yle:
normal'><span lang=3DUK style=3D'font-size:12.0pt;font-family:"Times New Ro=
man","serif";
mso-fareast-font-family:"Times New Roman";mso-fareast-language:UK'>З боку <=
span
style=3D'mso-bidi-font-style:italic'>нервової системи</span>:</span></i><sp=
an
lang=3DUK style=3D'font-size:12.0pt;font-family:"Times New Roman","serif";
mso-fareast-font-family:"Times New Roman"'> нечасто –</span><span lang=3DUK
style=3D'font-size:12.0pt;font-family:"Times New Roman","serif";mso-fareast=
-font-family:
"Times New Roman";mso-fareast-language:UK'> запаморочення,<i style=3D'mso-b=
idi-font-style:
normal'> </i>головний біль.<span style=3D'mso-tab-count:1'>                =
     </span><o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal'><i style=3D'mso-bidi-font-style:normal'><span
lang=3DUK style=3D'font-size:12.0pt;font-family:"Times New Roman","serif";
mso-fareast-font-family:"Times New Roman";mso-fareast-language:UK'>З боку ш=
кіри
та підшкірної клітковини: </span></i><span lang=3DUK style=3D'font-size:12.=
0pt;
font-family:"Times New Roman","serif";mso-fareast-font-family:"Times New Ro=
man";
mso-fareast-language:UK'>нечасто – висипання.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal'><i style=3D'mso-bidi-font-style:normal'><span
lang=3DUK style=3D'font-size:12.0pt;font-family:"Times New Roman","serif";
mso-fareast-font-family:"Times New Roman";mso-fareast-language:UK'>Лаборато=
рні
дослідження:</span></i><span lang=3DUK style=3D'font-size:12.0pt;font-famil=
y:"Times New Roman","serif";
mso-fareast-font-family:"Times New Roman"'> нечасто </span><span lang=3DUK
style=3D'font-size:12.0pt;font-family:"Times New Roman","serif";mso-fareast=
-font-family:
"Arial Unicode MS"'>–</span><span lang=3DUK style=3D'font-size:12.0pt;font-=
family:
"Times New Roman","serif";mso-fareast-font-family:"Times New Roman"'>
підвищений рівень амінотрансферази, знижена кількість білих кров'яних тілец=
ь.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal;page-break-after:avoid;mso-outline-level:1'><span
lang=3DUK style=3D'font-size:12.0pt;font-family:"Times New Roman","serif";
mso-fareast-font-family:"Times New Roman";mso-fareast-language:UK;mso-bidi-=
font-weight:
bold'>Побічні реакції зі спонтанних повідомлень,<b> </b></span><span lang=
=3DUK
style=3D'font-size:12.0pt;font-family:"Times New Roman","serif";mso-fareast=
-font-family:
"Times New Roman";mso-bidi-font-weight:bold;mso-bidi-font-style:italic'>про=
 які
повідомляли у ході<span style=3D'mso-spacerun:yes'>  </span>постмаркетингов=
ого
застосування<i>. </i></span><b><span lang=3DUK style=3D'font-size:12.0pt;
font-family:"Times New Roman","serif";mso-fareast-font-family:"Times New Ro=
man"'><span
style=3D'mso-spacerun:yes'> </span></span></b><i><span lang=3DUK style=3D'f=
ont-size:
12.0pt;font-family:"Times New Roman","serif";mso-fareast-font-family:"Times=
 New Roman";
mso-bidi-font-weight:bold'>Неможливо точно оцінити частоту виникнення за
наявними даними.</span></i><i><span lang=3DUK style=3D'font-size:12.0pt;fon=
t-family:
"Times New Roman","serif";mso-fareast-font-family:"Times New Roman";mso-far=
east-language:
UK;mso-bidi-font-weight:bold'><o:p></o:p></span></i></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal;page-break-after:avoid;mso-outline-level:1'><i><=
span
lang=3DUK style=3D'font-size:12.0pt;font-family:"Times New Roman","serif";
mso-fareast-font-family:"Times New Roman";mso-fareast-language:UK;mso-bidi-=
font-weight:
bold'>З<span style=3D'mso-spacerun:yes'>  </span>боку системи крові та
лімфатичної системи</span></i><i style=3D'mso-bidi-font-style:normal'><span
lang=3DUK style=3D'font-size:12.0pt;font-family:"Times New Roman","serif";
mso-fareast-font-family:"Times New Roman";mso-fareast-language:UK;mso-bidi-=
font-weight:
bold'>:</span></i><span lang=3DUK style=3D'font-size:12.0pt;font-family:"Ti=
mes New Roman","serif";
mso-fareast-font-family:"Times New Roman";mso-fareast-language:UK;mso-bidi-=
font-weight:
bold'> лейкопенія, тромбоцитопенія.</span><b><span lang=3DUK style=3D'font-=
size:
12.0pt;font-family:"Times New Roman","serif";mso-fareast-font-family:"Times=
 New Roman"'><o:p></o:p></span></b></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal'><i style=3D'mso-bidi-font-style:normal'><span
lang=3DUK style=3D'font-size:12.0pt;font-family:"Times New Roman","serif";
mso-fareast-font-family:"Times New Roman";mso-bidi-language:BO'>З<span
style=3D'mso-spacerun:yes'>  </span>боку імунної системи:</span></i><span
lang=3DUK style=3D'font-size:12.0pt;font-family:"Times New Roman","serif";
mso-fareast-font-family:"Times New Roman"'> </span><span lang=3DUK
style=3D'font-size:12.0pt;font-family:"Times New Roman","serif";mso-fareast=
-font-family:
"Times New Roman";mso-bidi-language:BO'>гіперчутливість, включаючи<i
style=3D'mso-bidi-font-style:normal'> </i>анафілактоїдну реакцію.<o:p></o:p=
></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal'><i style=3D'mso-bidi-font-style:normal'><span
lang=3DUK style=3D'font-size:12.0pt;font-family:"Times New Roman","serif";
mso-fareast-font-family:"Times New Roman";mso-bidi-language:BO'>З<span
style=3D'mso-spacerun:yes'>  </span>боку ендокринної системи: </span></i><s=
pan
lang=3DUK style=3D'font-size:12.0pt;font-family:"Times New Roman","serif";
mso-fareast-font-family:"Times New Roman";mso-bidi-language:BO'>підвищений
рівень пролактину в крові.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal'><i style=3D'mso-bidi-font-style:normal'><span
lang=3DUK style=3D'font-size:12.0pt;font-family:"Times New Roman","serif";
mso-fareast-font-family:"Times New Roman";mso-bidi-language:BO'>З<span
style=3D'mso-spacerun:yes'>  </span>боку нервової системи: </span></i><span
lang=3DUK style=3D'font-size:12.0pt;font-family:"Times New Roman","serif";
mso-fareast-font-family:"Times New Roman";mso-bidi-language:BO'>запаморочен=
ня,
головний біль, тремор.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal'><i style=3D'mso-bidi-font-style:normal'><span
lang=3DUK style=3D'font-size:12.0pt;font-family:"Times New Roman","serif";
mso-fareast-font-family:"Times New Roman";mso-bidi-language:BO'>З боку трав=
ної
системи: </span></i><span lang=3DUK style=3D'font-size:12.0pt;font-family:"=
Times New Roman","serif";
mso-fareast-font-family:"Times New Roman";mso-bidi-language:BO'>діарея, зап=
ор,
біль у животі, підвищене слиновиділення, нудота.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal'><i style=3D'mso-bidi-font-style:normal'><span
lang=3DUK style=3D'font-size:12.0pt;font-family:"Times New Roman","serif";
mso-fareast-font-family:"Times New Roman";mso-bidi-language:BO'>З боку печі=
нки
та жовчовивідних шляхів: </span></i><span lang=3DUK style=3D'font-size:12.0=
pt;
font-family:"Times New Roman","serif";mso-fareast-font-family:"Times New Ro=
man";
mso-bidi-language:BO'>жовтяниця.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal'><i style=3D'mso-bidi-font-style:normal'><span
lang=3DUK style=3D'font-size:12.0pt;font-family:"Times New Roman","serif";
mso-fareast-font-family:"Times New Roman";mso-fareast-language:UK'>З<span
style=3D'mso-spacerun:yes'>  </span>боку шкіри і підшкірної клітковини: </s=
pan></i><span
lang=3DUK style=3D'font-size:12.0pt;font-family:"Times New Roman","serif";
mso-fareast-font-family:"Times New Roman";mso-fareast-language:UK'>висипанн=
я,
еритема і свербіж. <o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal'><i style=3D'mso-bidi-font-style:normal'><span
lang=3DUK style=3D'font-size:12.0pt;font-family:"Times New Roman","serif";
mso-fareast-font-family:"Times New Roman";mso-fareast-language:UK'>З боку
репродуктивної системи та молочних залоз: </span></i><span lang=3DUK
style=3D'font-size:12.0pt;font-family:"Times New Roman","serif";mso-fareast=
-font-family:
"Times New Roman";mso-fareast-language:UK'>гінекомастія.<i style=3D'mso-bid=
i-font-style:
normal'><o:p></o:p></i></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal'><i style=3D'mso-bidi-font-style:normal'><span
lang=3DUK style=3D'font-size:12.0pt;font-family:"Times New Roman","serif";
mso-fareast-font-family:"Times New Roman";mso-fareast-language:UK'>Лаборато=
рні
дослідження: </span></i><span lang=3DUK style=3D'font-size:12.0pt;font-fami=
ly:"Times New Roman","serif";
mso-fareast-font-family:"Times New Roman";mso-fareast-language:UK'>підвищен=
ня
рівнів АСТ, АЛТ, ГГТ, лужної фосфатази, білірубіну в крові.<o:p></o:p></spa=
n></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal'><b><i><span lang=3DUK style=3D'font-size:12.0pt;
font-family:"Times New Roman","serif";mso-fareast-font-family:"Times New Ro=
man"'><o:p>&nbsp;</o:p></span></i></b></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal'><b style=3D'mso-bidi-font-weight:normal'><i
style=3D'mso-bidi-font-style:normal'><span lang=3DUK style=3D'font-size:12.=
0pt;
font-family:"Times New Roman","serif";mso-fareast-font-family:"Times New Ro=
man"'>Термін
придатності.</span></i></b><i style=3D'mso-bidi-font-style:normal'><span la=
ng=3DUK
style=3D'font-size:12.0pt;font-family:"Times New Roman","serif";mso-fareast=
-font-family:
"Times New Roman"'> </span></i><span lang=3DUK style=3D'font-size:12.0pt;
font-family:"Times New Roman","serif";mso-fareast-font-family:"Times New Ro=
man"'>2
роки.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal'><span lang=3DUK style=3D'font-size:12.0pt;font-=
family:
"Times New Roman","serif";mso-fareast-font-family:"Times New Roman"'><o:p>&=
nbsp;</o:p></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal'><b style=3D'mso-bidi-font-weight:normal'><span
lang=3DUK style=3D'font-size:12.0pt;font-family:"Times New Roman","serif";
mso-fareast-font-family:"Times New Roman"'>Умови зберігання. <o:p></o:p></s=
pan></b></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal;mso-layout-grid-align:none;punctuation-wrap:simp=
le;
text-autospace:none'><span lang=3DUK style=3D'font-size:12.0pt;font-family:=
"Times New Roman","serif";
mso-fareast-font-family:"Arial Unicode MS"'>Зберігати при температурі не ви=
ще
30 °C в оригінальній упаковці з метою захисту від вологи. Зберігати у
недоступному для дітей місці.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal;mso-layout-grid-align:none;punctuation-wrap:simp=
le;
text-autospace:none'><b><span lang=3DUK style=3D'font-size:12.0pt;font-fami=
ly:"Times New Roman","serif";
mso-fareast-font-family:"Times New Roman"'><o:p>&nbsp;</o:p></span></b></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal;mso-layout-grid-align:none;punctuation-wrap:simp=
le;
text-autospace:none'><b><span lang=3DUK style=3D'font-size:12.0pt;font-fami=
ly:"Times New Roman","serif";
mso-fareast-font-family:"Times New Roman"'>Упаковка</span></b><b
style=3D'mso-bidi-font-weight:normal'><span lang=3DUK style=3D'font-size:12=
.0pt;
font-family:"Times New Roman","serif";mso-fareast-font-family:"Times New Ro=
man"'>.<span
style=3D'mso-bidi-font-weight:bold'> <o:p></o:p></span></span></b></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal'><span lang=3DUK style=3D'font-size:12.0pt;font-=
family:
"Times New Roman","serif";mso-fareast-font-family:"Arial Unicode MS"'>По 10
таблеток у блістері; по 1 або по 4, або по 10 блістерів у картонну пачку.<o=
:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal'><b style=3D'mso-bidi-font-weight:normal'><span
lang=3DUK style=3D'font-size:12.0pt;font-family:"Times New Roman","serif";
mso-fareast-font-family:"Arial Unicode MS"'><o:p>&nbsp;</o:p></span></b></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal'><b style=3D'mso-bidi-font-weight:normal'><span
lang=3DUK style=3D'font-size:12.0pt;font-family:"Times New Roman","serif";
mso-fareast-font-family:"Arial Unicode MS"'>Категорія відпуску.</span></b><=
span
lang=3DUK style=3D'font-size:12.0pt;font-family:"Times New Roman","serif";
mso-fareast-font-family:"Arial Unicode MS"'> <o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal'><span lang=3DUK style=3D'font-size:12.0pt;font-=
family:
"Times New Roman","serif";mso-fareast-font-family:"Arial Unicode MS"'>За
рецептом.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal'><b><span lang=3DUK style=3D'font-size:12.0pt;
font-family:"Times New Roman","serif";mso-fareast-font-family:"Times New Ro=
man"'><o:p>&nbsp;</o:p></span></b></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal'><b><span lang=3DUK style=3D'font-size:12.0pt;
font-family:"Times New Roman","serif";mso-fareast-font-family:"Times New Ro=
man"'>Виробник.</span></b><span
lang=3DUK style=3D'font-size:12.0pt;font-family:"Times New Roman","serif";
mso-fareast-font-family:"Times New Roman"'> <span style=3D'mso-bidi-font-we=
ight:
bold'><o:p></o:p></span></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal'><span lang=3DUK style=3D'font-size:12.0pt;font-=
family:
"Times New Roman","serif";mso-fareast-font-family:"Times New Roman"'>Санека
Фармасьютікалз АТ.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal'><span lang=3DUK style=3D'font-size:12.0pt;font-=
family:
"Times New Roman","serif";mso-fareast-font-family:"Times New Roman"'><o:p>&=
nbsp;</o:p></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal'><b style=3D'mso-bidi-font-weight:normal'><span
lang=3DUK style=3D'font-size:12.0pt;font-family:"Times New Roman","serif";
mso-fareast-font-family:"Times New Roman"'>Місцезнаходження виробника та ад=
реса
місця провадження його діяльності.</span></b><a name=3D"OLE_LINK1"></a><a
name=3D"OLE_LINK2"><span style=3D'mso-bookmark:OLE_LINK1'><span lang=3DUK
style=3D'font-size:12.0pt;font-family:"Times New Roman","serif";mso-fareast=
-font-family:
"Times New Roman"'> </span></span></a><span lang=3DUK style=3D'font-size:12=
.0pt;
font-family:"Times New Roman","serif";mso-fareast-font-family:"Times New Ro=
man"'><o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt'><span
lang=3DUK style=3D'font-size:12.0pt;line-height:106%;font-family:"Times New=
 Roman","serif";
mso-fareast-font-family:"Times New Roman"'>Нітрянська 100, 920 27 Глоговець,
Словацька Республіка.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal'><b style=3D'mso-bidi-font-weight:normal'><span
lang=3DUK style=3D'font-size:12.0pt;font-family:"Times New Roman","serif";
mso-fareast-font-family:"Times New Roman";mso-fareast-language:RU'><o:p>&nb=
sp;</o:p></span></b></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal'><b style=3D'mso-bidi-font-weight:normal'><span
lang=3DUK style=3D'font-size:12.0pt;font-family:"Times New Roman","serif";
mso-fareast-font-family:"Times New Roman";mso-fareast-language:RU'>Заявник.=
</span></b><b
style=3D'mso-bidi-font-weight:normal'><span lang=3DUK style=3D'font-size:12=
.0pt;
font-family:"Times New Roman","serif";mso-fareast-font-family:"Times New Ro=
man";
mso-ansi-language:RU;mso-fareast-language:RU'> </span></b><span lang=3DUK
style=3D'font-size:12.0pt;font-family:"Times New Roman","serif";mso-fareast=
-font-family:
"MS Mincho";mso-fareast-language:JA'>АТ «Фармак».</span><span lang=3DUK
style=3D'font-size:12.0pt;font-family:"Times New Roman","serif";mso-fareast=
-font-family:
"Times New Roman";mso-fareast-language:RU'><o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;line-=
height:
normal'><b style=3D'mso-bidi-font-weight:normal'><span lang=3DUK style=3D'f=
ont-size:
12.0pt;font-family:"Times New Roman","serif";mso-fareast-font-family:"MS Mi=
ncho";
mso-fareast-language:JA'><o:p>&nbsp;</o:p></span></b></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;line-=
height:
normal'><b style=3D'mso-bidi-font-weight:normal'><span lang=3DUK style=3D'f=
ont-size:
12.0pt;font-family:"Times New Roman","serif";mso-fareast-font-family:"MS Mi=
ncho";
mso-fareast-language:JA'>Мiсцезнаходження заявника. </span></b><span lang=
=3DUK
style=3D'font-size:12.0pt;font-family:"Times New Roman","serif";mso-fareast=
-font-family:
"Times New Roman";mso-fareast-language:RU'>Україна,<b style=3D'mso-bidi-fon=
t-weight:
normal'> </b></span><span lang=3DUK style=3D'font-size:12.0pt;font-family:"=
Times New Roman","serif";
mso-fareast-font-family:"Times New Roman";mso-fareast-language:UK'>04080, м.
Київ, вул. </span><span style=3D'font-size:12.0pt;font-family:"Times New Ro=
man","serif";
mso-fareast-font-family:"Times New Roman";mso-ansi-language:RU;mso-fareast-=
language:
UK'>Кирил</span><span lang=3DUK style=3D'font-size:12.0pt;font-family:"Time=
s New Roman","serif";
mso-fareast-font-family:"Times New Roman";mso-fareast-language:UK'>івська, =
63.<o:p></o:p></span></p>

</div>

</body>

</html>

------=_NextPart_01DA20AF.DA67EAE0
Content-Location: file:///C:/6811E755/UA174580101_B895.files/preview.wmf
Content-Transfer-Encoding: base64
Content-Type: image/x-wmf
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=

------=_NextPart_01DA20AF.DA67EAE0
Content-Location: file:///C:/6811E755/UA174580101_B895.files/themedata.thmx
Content-Transfer-Encoding: base64
Content-Type: application/vnd.ms-officetheme

UEsDBBQABgAIAAAAIQDp3g+//wAAABwCAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKyRy07DMBBF
90j8g+UtSpyyQAgl6YLHjseifMDImSQWydiyp1X790zSVEKoIBZsLNkz954743K9Hwe1w5icp0qv
8kIrJOsbR12l3zdP2a1WiYEaGDxhpQ+Y9Lq+vCg3h4BJiZpSpXvmcGdMsj2OkHIfkKTS+jgCyzV2
JoD9gA7NdVHcGOuJkTjjyUPX5QO2sB1YPe7l+Zgk4pC0uj82TqxKQwiDs8CS1Oyo+UbJFkIuyrkn
9S6kK4mhzVnCVPkZsOheZTXRNajeIPILjBLDsAyJX89nIBkt5r87nons29ZZbLzdjrKOfDZezE7B
/xRg9T/oE9PMf1t/AgAA//8DAFBLAwQUAAYACAAAACEApdan58AAAAA2AQAACwAAAF9yZWxzLy5y
ZWxzhI/PasMwDIfvhb2D0X1R0sMYJXYvpZBDL6N9AOEof2giG9sb69tPxwYKuwiEpO/3qT3+rov5
4ZTnIBaaqgbD4kM/y2jhdj2/f4LJhaSnJQhbeHCGo3vbtV+8UNGjPM0xG6VItjCVEg+I2U+8Uq5C
ZNHJENJKRds0YiR/p5FxX9cfmJ4Z4DZM0/UWUtc3YK6PqMn/s8MwzJ5PwX+vLOVFBG43lExp5GKh
qC/jU72QqGWq1B7Qtbj51v0BAAD//wMAUEsDBBQABgAIAAAAIQBreZYWgwAAAIoAAAAcAAAAdGhl
bWUvdGhlbWUvdGhlbWVNYW5hZ2VyLnhtbAzMTQrDIBBA4X2hd5DZN2O7KEVissuuu/YAQ5waQceg
0p/b1+XjgzfO3xTVm0sNWSycBw2KZc0uiLfwfCynG6jaSBzFLGzhxxXm6XgYybSNE99JyHNRfSPV
kIWttd0g1rUr1SHvLN1euSRqPYtHV+jT9yniResrJgoCOP0BAAD//wMAUEsDBBQABgAIAAAAIQCl
Xn0txwYAANcbAAAWAAAAdGhlbWUvdGhlbWUvdGhlbWUxLnhtbOxZz24bRRi/I/EOo723sRMnjaM6
VezYDbRpo9gt6nG8Hu9OM7uzmhkn9a1Kj0ggREEcqARcOCAgUou4tO/gPkOgCIrUV+Cbmd31Tryh
SRtBBc0h3p39ff//zDe7Fy/diRjaJUJSHje86vmKh0js8wGNg4Z3o9c5t+whqXA8wIzHpOGNifQu
rb77zkW8okISEQT0sVzBDS9UKlmZm5M+LGN5nickhmdDLiKs4FYEcwOB94BvxObmK5WluQjT2EMx
joDt5JvJT5PHkwN0fTikPvFWM/5tBkJiJfWCz0RXcycZ0ddP9ycHkyeTR5ODp3fh+gn8fmxoBztV
TSHHssUE2sWs4YHoAd/rkTvKQwxLBQ8aXsX8eXOrF+fwSkrE1DG0BbqO+UvpUoLBzryRKYJ+LrTa
qdUvrOf8DYCpWVy73W61qzk/A8C+D5ZbXYo8a53lajPjWQDZy1nercpipebiC/wXZnSuN5vNxXqq
i2VqQPayNoNfrizV1uYdvAFZ/OIMvtZca7WWHLwBWfzSDL5zob5Uc/EGFDIa78ygdUA7nZR7Dhly
tlEKXwb4ciWFT1GQDXm2aRFDHquT5l6Eb3PRAQJNyLCiMVLjhAyxD4newlFfUKwF4hWCC0/ski9n
lrRsJH1BE9Xw3k8wFM2U34vH3794/BAd7j863P/58N69w/0fLSOHagPHQZHq+bef/PngLvrj4VfP
739WjpdF/K8/fPjLk0/LgVBOU3WefX7w26ODZ1989Pt390vgawL3i/AejYhE18ge2uYRGGa84mpO
+uJ0FL0Q0yLFWhxIHGMtpYR/W4UO+toYszQ6jh5N4nrwpoB2Uga8PLrtKNwNxUjREslXwsgBbnLO
mlyUeuGKllVwc28UB+XCxaiI28Z4t0x2C8dOfNujBPpqlpaO4a2QOGpuMRwrHJCYKKSf8R1CSqy7
Ranj103qCy75UKFbFDUxLXVJj/adbJoSbdAI4jIusxni7fhm8yZqclZm9TrZdZFQFZiVKN8jzHHj
ZTxSOCpj2cMRKzr8KlZhmZLdsfCLuLZUEOmAMI7aAyJlGc11AfYWgn4FQwcrDfsmG0cuUii6U8bz
Kua8iFznO60QR0kZtkvjsIh9T+5AimK0xVUZfJO7FaLvIQ44PjbcNylxwv3ybnCDBo5K0wTRT0ai
JJaXCXfytztmQ0xMq4Em7/TqiMZ/17gZhc5tJZxd44ZW+ezLByV6v6ktew12r7Ka2TjSqI/DHW3P
LS4G9M3vzut4FG8RKIjZLeptc37bnL3/fHM+rp7PviVPuzA0aD2L2MHbjOHRiafwIWWsq8aMXJVm
EJewFw06sKj5mEMqyU9pSQiXurJBoIMLBDY0SHD1AVVhN8QJDPFVTzMJZMo6kCjhEg6TZrmUt8bD
QUDZo+iiPqTYTiKx2uQDu7ygl7OzSM7GaBWYA3AmaEEzOKmwhQspU7DtVYRVtVInllY1qpkm6UjL
TdYuNod4cHluGizm3oQhB8FoBF5egtcEWjQcfjAjA+13G6MsLCYKZxkiGeIBSWOk7Z6NUdUEKcuV
GUO0HTYZ9MHyJV4rSKtrtq8h7SRBKoqrHSMui97rRCnL4GmUgNvRcmRxsThZjPYaXn1xftFDPk4a
3hDOzXAZJRB1qedKzAJ4P+UrYdP+pcVsqnwazXpmmFsEVXg1Yv0+Y7DTBxIh1TqWoU0N8yhNARZr
SVb/+UVw61kZUNKNTqbFwjIkw7+mBfjRDS0ZDomvisEurGjf2du0lfKRIqIbDvZQn43ENobw61QF
ewZUwusP0xH0Dby70942j9zmnBZd8Y2Zwdl1zJIQp+1Wl2hWyRZuGlKug7krqAe2lepujDu9Kabk
z8iUYhr/z0zR+wm8jVgY6Aj48DZZYKQrpeFxoUIOXSgJqd8RMEiY3gHZAu9/4TEkFbzTNr+C7Opf
W3OWhylrOFSqbRogQWE/UqEgZAvaksm+lzCrpnuXZclSRiajCurKxKrdJ7uE9XQPXNJ7u4dCSHXT
TdI2YHBH88+9TyuoH+ghp1hvTifL915bA//05GOLGYxy+7AZaDL/5yrm48F0V7X0hjzbe4uG6AfT
MauWVQUIK2wF9bTsX1GFU261tmPNWDy/mCkHUZy1GBbzgSiBd0pI/4P9jwqf2a8jekPt8W3orQg+
bmhmkDaQ1efs4IF0g7SLfRic7KJNJs3KujYdnbTXss36jCfdXO4RZ2vNThLvUzo7H85ccU4tnqWz
Uw87vrZrx7oaInu0RGFpmB1sTGDMl7Xily/evw2BXodvCCOmpEkm+I4lMMzQXVMHUPxWoiFd/QsA
AP//AwBQSwMEFAAGAAgAAAAhAA3RkJ+2AAAAGwEAACcAAAB0aGVtZS90aGVtZS9fcmVscy90aGVt
ZU1hbmFnZXIueG1sLnJlbHOEj00KwjAUhPeCdwhvb9O6EJEm3YjQrdQDhOQ1DTY/JFHs7Q2uLAgu
h2G+mWm7l53JE2My3jFoqhoIOumVcZrBbbjsjkBSFk6J2TtksGCCjm837RVnkUsoTSYkUiguMZhy
DidKk5zQilT5gK44o49W5CKjpkHIu9BI93V9oPGbAXzFJL1iEHvVABmWUJr/s/04GolnLx8WXf5R
QXPZhQUoosbM4CObqkwEylu6usTfAAAA//8DAFBLAQItABQABgAIAAAAIQDp3g+//wAAABwCAAAT
AAAAAAAAAAAAAAAAAAAAAABbQ29udGVudF9UeXBlc10ueG1sUEsBAi0AFAAGAAgAAAAhAKXWp+fA
AAAANgEAAAsAAAAAAAAAAAAAAAAAMAEAAF9yZWxzLy5yZWxzUEsBAi0AFAAGAAgAAAAhAGt5lhaD
AAAAigAAABwAAAAAAAAAAAAAAAAAGQIAAHRoZW1lL3RoZW1lL3RoZW1lTWFuYWdlci54bWxQSwEC
LQAUAAYACAAAACEApV59LccGAADXGwAAFgAAAAAAAAAAAAAAAADWAgAAdGhlbWUvdGhlbWUvdGhl
bWUxLnhtbFBLAQItABQABgAIAAAAIQAN0ZCftgAAABsBAAAnAAAAAAAAAAAAAAAAANEJAAB0aGVt
ZS90aGVtZS9fcmVscy90aGVtZU1hbmFnZXIueG1sLnJlbHNQSwUGAAAAAAUABQBdAQAAzAoAAAAA

------=_NextPart_01DA20AF.DA67EAE0
Content-Location: file:///C:/6811E755/UA174580101_B895.files/colorschememapping.xml
Content-Transfer-Encoding: quoted-printable
Content-Type: text/xml

<?xml version=3D"1.0" encoding=3D"UTF-8" standalone=3D"yes"?>
<a:clrMap xmlns:a=3D"http://schemas.openxmlformats.org/drawingml/2006/main"=
 bg1=3D"lt1" tx1=3D"dk1" bg2=3D"lt2" tx2=3D"dk2" accent1=3D"accent1" accent=
2=3D"accent2" accent3=3D"accent3" accent4=3D"accent4" accent5=3D"accent5" a=
ccent6=3D"accent6" hlink=3D"hlink" folHlink=3D"folHlink"/>
------=_NextPart_01DA20AF.DA67EAE0
Content-Location: file:///C:/6811E755/UA174580101_B895.files/header.htm
Content-Transfer-Encoding: quoted-printable
Content-Type: text/html; charset="windows-1251"

<html xmlns:v=3D"urn:schemas-microsoft-com:vml"
xmlns:o=3D"urn:schemas-microsoft-com:office:office"
xmlns:w=3D"urn:schemas-microsoft-com:office:word"
xmlns:m=3D"http://schemas.microsoft.com/office/2004/12/omml"
xmlns=3D"http://www.w3.org/TR/REC-html40">

<head>
<meta http-equiv=3DContent-Type content=3D"text/html; charset=3Dwindows-125=
1">
<meta name=3DProgId content=3DWord.Document>
<meta name=3DGenerator content=3D"Microsoft Word 14">
<meta name=3DOriginator content=3D"Microsoft Word 14">
<link id=3DMain-File rel=3DMain-File href=3D"../UA174580101_B895.htm">
<![if IE]>
<base href=3D"file:///C:\6811E755\UA174580101_B895.files\header.htm"
id=3D"webarch_temp_base_tag">
<![endif]>
</head>

<body lang=3DRU>

<div style=3D'mso-element:footnote-separator' id=3Dfs>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;line-=
height:
normal'><span lang=3DUK><span style=3D'mso-special-character:footnote-separ=
ator'><![if !supportFootnotes]>

<hr align=3Dleft size=3D1 width=3D"33%">

<![endif]></span></span></p>

</div>

<div style=3D'mso-element:footnote-continuation-separator' id=3Dfcs>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;line-=
height:
normal'><span lang=3DUK><span style=3D'mso-special-character:footnote-conti=
nuation-separator'><![if !supportFootnotes]>

<hr align=3Dleft size=3D1>

<![endif]></span></span></p>

</div>

<div style=3D'mso-element:endnote-separator' id=3Des>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;line-=
height:
normal'><span lang=3DUK><span style=3D'mso-special-character:footnote-separ=
ator'><![if !supportFootnotes]>

<hr align=3Dleft size=3D1 width=3D"33%">

<![endif]></span></span></p>

</div>

<div style=3D'mso-element:endnote-continuation-separator' id=3Decs>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;line-=
height:
normal'><span lang=3DUK><span style=3D'mso-special-character:footnote-conti=
nuation-separator'><![if !supportFootnotes]>

<hr align=3Dleft size=3D1>

<![endif]></span></span></p>

</div>

<div style=3D'mso-element:footer' id=3Df1>

<p class=3DMsoFooter align=3Dcenter style=3D'text-align:center'><!--[if sup=
portFields]><span
lang=3DUK style=3D'font-family:"Times New Roman","serif"'><span style=3D'ms=
o-element:
field-begin'></span>PAGE<span style=3D'mso-spacerun:yes'>   </span>\* MERGE=
FORMAT<span
style=3D'mso-element:field-separator'></span></span><![endif]--><span
style=3D'font-family:"Times New Roman","serif";mso-ansi-language:RU;mso-no-=
proof:
yes'>1</span><!--[if supportFields]><span lang=3DUK style=3D'font-family:"T=
imes New Roman","serif"'><span
style=3D'mso-element:field-end'></span></span><![endif]--><span lang=3DUK
style=3D'font-family:"Times New Roman","serif"'><o:p></o:p></span></p>

<p class=3DMsoFooter><span lang=3DUK><o:p>&nbsp;</o:p></span></p>

</div>

</body>

</html>

------=_NextPart_01DA20AF.DA67EAE0
Content-Location: file:///C:/6811E755/UA174580101_B895.files/filelist.xml
Content-Transfer-Encoding: quoted-printable
Content-Type: text/xml; charset="utf-8"

<xml xmlns:o=3D"urn:schemas-microsoft-com:office:office">
 <o:MainFile HRef=3D"../UA174580101_B895.htm"/>
 <o:File HRef=3D"preview.wmf"/>
 <o:File HRef=3D"themedata.thmx"/>
 <o:File HRef=3D"colorschememapping.xml"/>
 <o:File HRef=3D"header.htm"/>
 <o:File HRef=3D"filelist.xml"/>
</xml>
------=_NextPart_01DA20AF.DA67EAE0--
